Anti-HER2 immunoconjugates and uses thereof
Patent Information
- Application Number
- JP2023534648
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-11
- Filing Date
- 2021-12-10
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2022125915000001 
Figure 2022125915000002 
Figure 2022125915000003
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the benefit of priority of U.S. Provisional Application No. 63 / 124,421, filed on 11 December 2020, which is incorporated in its entirety by reference.
[0002] The present invention generally relates to an immune complex comprising an anti-HER2 antibody conjugated to one or more 8-phenyl-2-aminobenzazepine molecules. [Background technology]
[0003] Novel compositions and methods for delivering antibodies and immunoadjuvants are needed to reach inaccessible tumors and / or to expand treatment options for cancer patients and other targets. This invention provides such compositions and methods. [Overview of the project]
[0004] The present invention generally relates to an immune complex comprising an anti-HER2 antibody conjugated to one or more 8-phenyl-2-aminobenzazepine derivatives. The present invention further relates to an 8-phenyl-2-aminobenzazepine derivative intermediate composition comprising a reactive functional group. Such an intermediate composition is a suitable substrate for the formation of an immune complex, and the antibody is linked by linker L to formula: [ka] It may be covalently bonded to the 8-phenyl-2-aminobenzazepine (PhBz) moiety having R, in the formula 1 , R 2 , R 3 , and R 4 One of them is bound to L. 1-4 Substituents and X 1-4 Substituents are defined herein.
[0005] The present invention further relates to the use of such immune complexes in the treatment of diseases, particularly cancer.
[0006] One aspect of the present invention is an immune complex comprising an anti-HER2 antibody covalently bound to one or more linkers covalently bound to an 8-Phe-2-aminobenzazepine moiety.
[0007] Another aspect of the present invention is an 8-phenyl-2-aminobenzazepine-linker compound.
[0008] Another aspect of the present invention is a method for treating cancer, comprising administering a therapeutically effective dose of an immune complex comprising one or more anti-HER2 antibodies conjugated to 8-Phe-2-aminobenzazepine moieties.
[0009] Another aspect of the present invention is the use of an immune complex comprising one or more anti-HER2 antibodies conjugated to an 8-Phe-2-aminobenzazepine moiety for the treatment of cancer.
[0010] Another aspect of the present invention is a method for preparing an immune complex by conjugation of an anti-HER2 antibody with one or more 8-Phe-2-aminobenzazepine moieties. [Modes for carrying out the invention]
[0011] Herein, certain embodiments of the present invention are described in detail, examples of which are illustrated in the attached structures and formulas. The present invention is described in conjunction with the listed embodiments, but it will be understood that they are not intended to limit the invention to those embodiments. Rather, the present invention is intended to encompass all substitutes, modifications, and equivalents that may fall within the scope of the invention as defined by the claims.
[0012] Those skilled in the art will recognize many methods and materials similar to or equivalent to those described herein that may be used in carrying out the present invention. The present invention is by no means limited to the methods and materials described herein.
[0013] definition The terms "immune complex" or "immunostimulating antibody complex" refer to antibody constructs that covalently bind to an adjuvant portion via a linker. The term "adjuvant" refers to a substance that can induce an immune response in a subject to which it is exposed.
[0014] The “adjuvant moiety” refers to an adjuvant that covalently binds to the antibody construct via a linker, for example, as described herein. The adjuvant moiety can induce an immune response while bound to the antibody construct or after cleavage (e.g., enzymatic cleavage) from the antibody construct following administration of the immune complex to a target.
[0015] An "adjuvant" refers to a substance that can induce an immune response in a subject to which it is exposed.
[0016] The terms "Toll-like receptor" and "TLR" refer to any member of a highly conserved family of mammalian proteins that recognize pathogen-associated molecular patterns and function as important signaling elements in innate immunity. TLR polypeptides share a characteristic structure that includes an extracellular domain with leucine-rich repeats, a transmembrane domain, and an intracellular domain involved in TLR signaling.
[0017] The terms “Tall-like receptor 7” and “TLR7” refer to nucleic acids or polypeptides that share at least about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or more sequence identity with publicly available TLR7 sequences, such as the GenBank acceptance number AAZ99026 for human TLR7 polypeptide or the GenBank acceptance number AAK62676 for mouse TLR7 polypeptide.
[0018] The terms "Tall-like receptor 8" and "TLR8" refer to nucleic acids or polypeptides that share at least approximately 70%, approximately 80%, approximately 90%, approximately 95%, approximately 96%, approximately 97%, approximately 98%, approximately 99%, or more sequence identity with publicly available TLR7 sequences, such as the GenBank acceptance number AAZ95441 for human TLR8 polypeptide or the GenBank acceptance number AAK62677 for mouse TLR8 polypeptide.
[0019] A "TLR agonist" is a substance that directly or indirectly binds to a TLR (e.g., TLR7 and / or TLR8) to induce TLR signaling. Any detectable difference in TLR signaling can indicate that an agonist stimulates or activates a TLR. Differences in signaling can manifest, for example, as the expression of a target gene, phosphorylation of signaling components, intracellular localization of downstream elements such as nuclear factor-κB (NF-κB), association of a specific component (e.g., IL-1 receptor-associated kinase (IRAK)) with other proteins or intracellular structures, or changes in the biochemical activity of a component such as a kinase (e.g., mitogen-activated protein kinase (MAPK)).
[0020] An "antibody" refers to a polypeptide containing an antigen-binding region (including complementarity-determining regions (CDRs)) from an immunoglobulin gene or a fragment thereof. Specifically, the term "antibody" encompasses monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments exhibiting desired biological activity. Exemplary immunoglobulin (antibody) structural units include tetramers. Each tetramer consists of two identical pairs of polypeptide chains, each pair having one "light" (approximately 25 kDa) and one "heavy" (approximately 50-70 kDa) chains linked by disulfide bonds. Each chain consists of structural domains called immunoglobulin domains. These domains have variable size and function, e.g., variable domains or regions on the light and heavy chains (V, respectively). L and V H) and the constant domains or regions on the light and heavy chains (C L and C H ), respectively, which are classified into different categories. The N-terminus of each chain defines a variable region of approximately 100 to 110 or more amino acids, which is mainly responsible for antigen recognition, i.e., the paratope that bears the antigen-binding domain. The light chain is classified into either kappa or lambda. The heavy chain is classified into gamma, mu, alpha, delta, or epsilon, which respectively define the immunoglobulin classes IgG, IgM, IgA, IgD, and IgE. An IgG antibody is a large molecule of approximately 150 kDa consisting of four peptide chains. An IgG antibody contains two identical class γ heavy chains of approximately 50 kDa and two identical light chains of approximately 25 kDa, and thus has a tetrameric quaternary structure. The two heavy chains are linked to each other by disulfide bonds and are each linked to a light chain. The resulting tetramer has two identical halves that together form a Y-like shape. Each end of the fork contains an identical antigen-binding domain. There are four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in humans, which are named in the order of their abundance in serum (i.e., IgG1 is the most abundant). Typically, the antigen-binding domain of an antibody will be the most important in terms of the specificity and affinity of binding to cancer cells.
[0021] An "antibody construct" refers to an antibody or fusion protein that includes (i) an antigen-binding domain and (ii) an Fc domain.
[0022] In some embodiments, the binder is an antigen-binding antibody "fragment", which is a construct that includes at least the antigen-binding region of an antibody, either alone or together with other components that make up the antigen-binding construct. For example, (i) a Fab fragment, which is a monovalent fragment consisting of V L , V H , C L , and the CH1 domain; (ii) an F(ab’)2 fragment, which is a bivalent fragment consisting of two Fab fragments linked by a disulfide bridge in the hinge region; (iii) V L and V H(iv) an Fv fragment consisting of domains, a Fab' fragment resulting from breaking the disulfide bridge of the F(ab')2 fragment using mild reducing conditions, (v) a disulfide-stabilized Fv fragment (dsFv), and (vi) two domains of the Fv fragment (i.e., V) linked by a synthetic linker that allows the two domains to be synthesized as a single polypeptide chain. L and V H Many different types of antibody "fragments," including single chains (scFv) which are monovalent molecules consisting of ), are known in the art.
[0023] An antibody or antibody fragment may be part of a larger construct, such as a complex or fusion construct of the antibody fragment into further regions. For example, in some embodiments, an antibody fragment may be fused to an Fc region as described herein. In other embodiments, an antibody fragment (e.g., Fab or scFv) may be part of a chimeric antigen receptor or chimeric T cell receptor by fusion, for example, to a transmembrane domain (optionally, together with an intervening linker or "stem" (e.g., hinge region)) and any intercellular signaling domain.
[0024] An "epitope" refers to any antigenic determinant or epitope determinant of an antigen to which an antigen-binding domain binds (i.e., in the paratope of the antigen-binding domain). Antigenic determinants typically consist of a chemically active surface group of a molecule, such as an amino acid or sugar side chain, and usually possess specific three-dimensional structural properties and specific charge properties.
[0025] The term "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. There are three main classes of Fc receptors: (1) FcγR that binds to IgG, (2) FcαR that binds to IgA, and (3) FcεR that binds to IgE. The FcγR family includes several members such as FcγI (CD64), FcγRIIA (CD32A), FcγRIIB (CD32B), FcγRIIIA (CD16A), and FcγRIIIB (CD16B). Fcγ receptors have different affinities to IgG and also have different affinities to IgG subclasses (e.g., IgG1, IgG2, IgG3, and IgG4).
[0026] Nucleic acid or amino acid sequence "identity" as referred to herein can be determined by comparing the nucleic acid or amino acid sequence of interest with a reference nucleic acid or amino acid sequence. Percent identity is calculated by dividing the number of identical (i.e., identical) nucleotide or amino acid residues between the optimally aligned sequence of interest and the reference sequence by the length of the longest sequence (i.e., whichever is longer, the length of the sequence of interest or the reference sequence). Sequence alignment and percentage identity calculations can be performed using available software programs. Examples of such programs include CLUSTAL-W, T-Coffee, ALIGN (for nucleic acid and amino acid sequence alignment), the BLAST program (e.g., BLAST2.1, BL2SEQ, BLASTp, BLASTn, etc.), and the FASTA program (e.g., FASTA3x, FASTM, and SSEARCH) (for sequence alignment and sequence similarity searches). Sequence alignment algorithms can be found in, for example, Altschul et al., J. Molecular Biol., 215(3):403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10):3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probalistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009), Soding, Bioinformatics, 21(7):951-960 (2005), Altschul et al., Nucleic Acids Res., 25(17):3389-3402 (1997), and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge. It is also disclosed in UK (1997). Percent (%) identity of sequences is also expressed, for example, 100 × [(identical position) / min(TG). A , TG B)] can be calculated as, in the formula, TG A and TG B , TG A and TG B This is the sum of the number of residues and internal gap positions in peptide sequences A and B during alignment that minimizes the ratio. See, for example, Russell et al., J. Mol Biol., 244:332-350 (1994).
[0027] The binder comprises an Ig heavy chain and light chain variable region polypeptide that together form an antigen-binding site. Each of the heavy chain and light chain variable region is a polypeptide containing three complementarity-determining regions (CDR1, CDR2, and CDR3) linked by a framework region. The binder may be any of the various types of binders known in the art that comprise the Ig heavy chain and light chain. For example, the binder may be an antibody, an antigen-binding antibody "fragment," or a T cell receptor.
[0028] "Biosimilar" refers to an approved antibody construct that has similar activity characteristics to HER2-targeted antibodies such as trastuzumab (HERCEPTIN®, Genentech, Inc.) or pertuzumab (PERJETA, Genentech, Inc.).
[0029] "Biobetter" refers to an approved antibody construct that is an improvement on a previously approved antibody construct, such as rabetuzumab. A biobetter may have one or more modifications to a previously approved antibody construct (e.g., an altered glycan profile or a unique epitope). A biobetter is a recombinant protein drug in the same class as existing biopharmaceuticals, but it is not identical and is superior to the original. A biobetter is neither a new drug nor a generic version of a drug. Both biosimilars and biobetters are variants of biological products; the former are close copies of the active pharmaceutical ingredient, while the latter are improved in terms of efficacy, safety, and tolerability or administration scheme.
[0030] "Amino acid" refers to any monomeric unit that can be incorporated into a peptide, polypeptide, or protein. Amino acids include naturally occurring α-amino acids and their stereoisomers, as well as unnatural (non-natural) amino acids and their stereoisomers. A "stereoisomer" of a given amino acid refers to an isomer that has the same molecular formula and intramolecular bonds but a different three-dimensional arrangement of bonds and atoms (e.g., an L-amino acid and its corresponding D-amino acid). Amino acids can be glycosylated (e.g., N-linked glycans, O-linked glycans, phosphoglycans, C-linked glycans, or glycosylation) or deglycosylated. Amino acids may be referred herein by either one of three commonly known letter symbols or one letter symbol recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
[0031] Naturally occurring amino acids include those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Naturally occurring α-amino acids include, but are not limited to, alanine (Ala), cysteine (Cys), aspartic acid (Asp), glutamic acid (Glu), phenylalanine (Phe), glycine (Gly), histidine (His), isoleucine (Ile), arginine (Arg), lysine (Lys), leucine (Leu), methionine (Met), asparagine (Asn), proline (Pro), glutamine (Gln), serine (Ser), threonine (Thr), valine (Val), tryptophan (Trp), tyrosine (Tyr), and combinations thereof. Naturally occurring stereoisomers of α-amino acids include, but are not limited to, D-alanine (D-Ala), D-cysteine (D-Cys), D-aspartic acid (D-Asp), D-glutamic acid (D-Glu), D-phenylalanine (D-Phe), D-histidine (D-His), D-isoleucine (D-Ile), D-arginine (D-Arg), D-lysine (D-Lys), D-leucine (D-Leu), D-methionine (D-Met), D-asparagine (D-Asn), D-proline (D-Pro), D-glutamine (D-Gln), D-serine (D-Ser), D-threonine (D-Thr), D-valine (D-Val), D-tryptophan (D-Trp), D-tyrosine (D-Tyr), and combinations thereof.
[0032] Naturally occurring amino acids include those that are formed in proteins through post-translational modifications such as citrulline (Cit).
[0033] Non-natural (non-naturally occurring) amino acids include, but are not limited to, amino acid analogs, amino acid mimes, synthetic amino acids, N-substituted glycines, and N-methylamino acids, all of which function in a similar manner to naturally occurring amino acids and have either an L or D configuration. For example, an "amino acid analog" may be a non-natural amino acid that has the same basic chemical structure as naturally occurring amino acids (i.e., hydrogen, a carboxyl group, and a carbon atom bonded to an amino group), but has a modified side chain group or a modified peptide skeleton, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. An "amino acid mime" refers to a compound that has a structure different from the general chemical structure of an amino acid, but functions in a similar manner to naturally occurring amino acids.
[0034] A "linker" refers to a functional group that covalently bonds two or more parts of a compound or material. For example, a linking part can play a role in covalently bonding an adjuvant part to an antibody construct in an immune complex.
[0035] A "linking group" refers to a functional group that covalently bonds two or more parts of a compound or material. For example, a linking group can play a role in covalently bonding an adjuvant to an antibody in an immune complex. Useful bonds for linking linking groups to proteins and other materials include, but are not limited to, amides, amines, esters, carbamates, ureas, thioethers, thiocarbamates, thiocarbonates, and thioureas.
[0036] "Divalent" refers to a chemical moiety containing two bonding sites for linking two functional groups, while a polyvalent bonded moiety may have additional bonding sites for linking further functional groups. Divalent radicals may be denoted by the suffix "diyl". For example, divalent bonded moieties include divalent polymer moieties such as divalent poly(ethylene glycol), divalent cycloalkyl, divalent heterocycloalkyl, divalent aryl, and divalent heteroaryl groups. "Divalent cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group" refers to a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group having two bonding sites for covalently linking two parts in a molecule or material. Cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups may be substituted or unsubstituted. Cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups may be substituted with one or more groups selected from halo, hydroxy, amino, alkylamino, amide, acyl, nitro, cyano, and alkoxy.
[0037] wavy line ( [ka] The symbol ) represents the bond point of the specified chemical part. If two wavy lines are present in the specified chemical part, it will be understood that the chemical part may be used to be read from both sides, i.e., from left to right or right to left.
[0038] "Alkyl" refers to a linear or branched saturated aliphatic radical having the number of carbon atoms indicated. Alkyls can contain any number of carbon atoms, for example, 1 to 12. Examples of alkyl groups include methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), and 2-methyl-2-propyl (t-Bu, t- Butyl, -C(CH3)3), 1-Pentyl (n-Pentyl, -CH2CH2CH2CH2CH3), 2-Pentyl (-CH(CH3)CH2CH2CH3), 3-Pentyl (-CH(CH2CH3)2), 2-Methyl-2-butyl (-C(CH3)2CH2CH3), 3-Methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-Methyl-1-butyl (-CH2CH2CH(CH3)2), 2-Methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-Hexyl (-CH2CH2 CH2CH2CH2CH3), 2-hexyl(-CH(CH3)CH2CH2CH2CH3), 3-hexyl(-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl(-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl(-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl(-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl(-CH(C Examples of alkyl groups include, but are not limited to, H2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl(-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl(-CH(CH3)C(CH3)3), 1-heptyl, and 1-octyl. The alkyl group may be substituted or unsubstituted. The "substituted alkyl" group may be substituted with one or more groups selected from halo, hydroxy, amino, oxo (=O), alkylamino, amide, acyl, nitro, cyano, and alkoxy.
[0039] The term "alkyldiyl" refers to a divalent alkyl radical. Examples of alkyldiyl groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), and propylene (-CH2CH2CH2-). Alkyldiyl groups can also be called "alkylene" groups.
[0040] An "alkenyl" refers to a linear or branched, unsaturated aliphatic radical having the indicated number of carbon atoms and at least one carbon-carbon double bond (sp2). Alkenyls may contain approximately 12 or more carbon atoms. Alkenyl groups are radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. Examples include, but are not limited to, etyleneyl or vinyl (-CH=CH2), allyl (-CH2CH=CH2), butenyl, pentenyl, and their isomers. Alkenyl groups may be substituted or unsubstituted. A "substituted alkenyl" group may be substituted with one or more groups selected from halo, hydroxy, amino, oxo (=O), alkylamino, amide, acyl, nitro, cyano, and alkoxy.
[0041] The terms "alkenylene" or "alkenyldiyl" refer to straight-chain or branched-chain divalent hydrocarbon radicals. Examples include, but are not limited to, ethylenylene or vinylene (-CH=CH-) and allyl (-CH2CH=CH-).
[0042] "Alkynyl" refers to a linear or branched unsaturated aliphatic radical having the indicated number of carbon atoms and at least one carbon-carbon triple bond, sp. Alkynnyls may contain about 12 or more carbon atoms. For example, C2-C6 alkynyls include, but are not limited to, ethynyl (-C≡CH), propynyl (propargyl, -CH2C≡CH), butynyl, pentynyl, hexynyl, and their isomers. The alkynyl group may be substituted or unsubstituted. A "substituted alkynyl" group may be substituted with one or more groups selected from halo, hydroxy, amino, oxo (=O), alkylamino, amide, acyl, nitro, cyano, and alkoxy.
[0043] The terms "alkynylene" or "alkynyldiyl" refer to divalent alkynyl radicals.
[0044] The terms “carbocyclic,” “carbocyclyl,” “carbocyclic ring,” and “cycloalkyl” refer to saturated or partially unsaturated, monocyclic, fused bicyclic, or bridging polycyclic ring assemblies containing 3 to 12 ring atoms, or the number of atoms indicated. Examples of saturated monocyclic carbocyclic rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Examples of saturated bicyclic and polycyclic carbocyclic rings include norbornane, [2.2.2]bicyclooctane, decahydronaphthalene, and adamantane. Carbocyclic groups may also be partially unsaturated, having one or more double or triple bonds within the ring. Representative partially unsaturated carbocyclic groups include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctadiene (1,3-, 1,4- and 1,5-isomers), norbornene, and norbornadiene.
[0045] The term "cycloalkyldiyl" refers to a divalent cycloalkyl radical.
[0046] "Aryl" is derived by removing one hydrogen atom from a single carbon atom in a hydrophilic aromatic ring system, resulting in a group of 6 to 20 carbon atoms (C6-C6). 20 This refers to a monovalent aromatic hydrocarbon radical. The aryl group may be monocyclic, condensed to form a bicyclic or tricyclic group, or linked by bonds to form a biaryl group. Typical aryl groups include phenyl, naphthyl, and biphenyl. Other aryl groups include benzyl, which has a methylene linkage group. Some aryl groups have 6 to 12 ring members, such as phenyl, naphthyl, or biphenyl. Other aryl groups have 6 to 10 ring members, such as phenyl or naphthyl.
[0047] The term "alylene" or "aryldiyl" refers to a group of 6 to 20 carbon atoms (C6-C) derived by removing two hydrogen atoms from two carbon atoms in a hydrophilic aromatic ring system. 20 This refers to a divalent aromatic hydrocarbon radical. Some aryldiyl groups are represented as "Ar" in exemplary structures. Aryldiyls include bicyclic radicals containing saturated, partially unsaturated rings, or aromatic rings condensed to aromatic carbocyclic rings. Typical aryldiyl groups include, but are not limited to, radicals derived from benzene (phenyldiyl), substituted benzenes, naphthalene, anthracene, biphenylene, indenylene, indanylene, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and others. The aryldiyl group is also referred to as "arylene" and is optionally substituted with one or more substituents described herein.
[0048] The terms “heterocyclic,” “heterocyclyl,” and “heterocyclic ring” are used interchangeably herein and refer to a saturated or partially unsaturated (i.e., having one or more double and / or triple bonds in the ring) carbocyclic radical of 3 to about 20 ring atoms, where at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, and the remaining ring atoms are carbon, one or more ring atoms are optionally independently substituted with one or more substituents as described below. The heterocyclic ring may be a monocyclic ring having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, and S), or a bicyclocyclic ring having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, and S), e.g., a bicyclo[4,5],[5,5],[5,6], or[6,6] system. Heterocyclic compounds are described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (WABenjamin, New York, 1968), particularly chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), particularly volumes 13, 14, 16, 19, and 28; and J.Am.Chem.Soc. (1960) 82:5566. “Heterocyclyls” also include radicals in which a heterocyclic radical is condensed with a saturated, partially unsaturated, or aromatic carbocyclic or heterocyclic ring.Examples of heterocyclic rings include morpholine-4-yl, piperidine-1-yl, piperazinyl, piperazine-4-yl-2-one, piperazine-4-yl-3-one, pyrrolidine-1-yl, thiomorpholine-4-yl, S-dioxothiomorpholine-4-yl, azocan-1-yl, azetidine-1-yl, octahydropyrido[1,2-a]pyrazine-2-yl, [1,4]diazepan-1-yl, pyrrolidinyl, tetrahydrofuranil, dihydrofuranil, tetrahydrothienyl, tetrahydropyranil, dihydropyranil, tetrahydrothiopyranil, piperidino, morpholino, thiomorpholino, thiooxanil, homopiperazinyl, azetidine Examples include, but are not limited to, oxetanil, thietanil, homopiperidinil, oxepanil, thiepanil, oxazepinil, diazepinil, thiazepinil, 2-pyrrolinil, 3-pyrrolinil, indolinil, 2H-pyranil, 4H-pyranil, dioxanil, 1,3-dioxolanil, pyrazolinil, dithianil, dithiolanil, dihydropyranil, dihydrothienyl, dihydrofuranil, pyrazolidinylimidazolinil, imidazolidinil, 3-azabicyclo[3.1.0]hexanil, 3-azabicyclo[4.1.0]heptanil, azabicyclo[2.2.2]hexanil, 3H-indollyquinolidinil, and N-pyridylurea. Spiroheterocyclyl moieties are also included within the scope of this definition. Examples of spiroheterocyclyl moieties include azaspiro[2.5]octanyl and azaspiro[2.4]heptanyl. Examples of heterocyclic groups in which two ring atoms are substituted with an oxo (=O) moiety are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocyclic groups herein are optionally and independently substituted with one or more substituents described herein.
[0049] The term "heterocyclyldiyl" refers to a divalent, saturated, or partially unsaturated (i.e., having one or more double and / or triple bonds in the ring) carbocyclic radical of 3 to about 20 ring atoms, where at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur, and the remaining ring atoms are carbon, and one or more ring atoms are optionally independently substituted with one or more substituents as described. Examples of 5-membered and 6-membered heterocyclyldiyl include morpholinyldiyl, piperidinyldiyl, piperazinyldiyl, pyrrolidinyldiyl, dioxanyldiyl, thiomorpholyldiyl, and S-dioxothiomorpholyldiyl.
[0050] The term "heteroaryl" refers to a monovalent aromatic radical with a 5, 6, or 7 member ring, and includes a condensed ring system of 5 to 20 atoms (at least one of which is aromatic) containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyridinyl (e.g., including 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (e.g., including 4-hydroxypyridinyl), pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinolinyl, indazolyl, indolidinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, thiadiazolyl, flazanyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthylidinyl, and flupyridinyl. The heteroaryl group is optionally and independently substituted with one or more substituents described herein.
[0051] The term "heteroaryldiyl" refers to a divalent aromatic radical of a 5, 6, or 7-membered ring, and includes 5 to 20 atom fused ring systems (at least one of which is aromatic) containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur. Examples of 5- and 6-membered heteroaryldiyls include pyridyldiyl, imidazolyldiyl, pyrimidyldiyl, pyrazolyldiyl, triazolyldiyl, pyrazinyldiyl, tetrazolyldiyl, furyldiyl, thienyldiyl, isoxazolyldiyl, thiazolyldiyl, oxadiazolyldiyl, oxazolyldiyl, isothiazolyldiyl, and pyrrolyldiyl.
[0052] The heterocyclic or heteroaryl group may, where possible, be bonded to carbon (carbon-linked) or nitrogen (nitrogen-linked). Examples, though not limited to, include the carbon-linked heterocyclic or heteroaryl groups bonded to positions 2, 3, 4, 5, or 6 of pyridine, positions 3, 4, 5, or 6 of pyridazine, positions 2, 4, 5, or 6 of pyrimidine, positions 2, 3, 5, or 6 of pyrazine, positions 2, 3, 5, or 5 of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole, or tetrahydropyrrole, positions 2, 3, 4, or 5 of oxazole, imidazole, or thiazole, positions 3, 4, or 5 of isoxazole, pyrazole, or isothiazole, positions 2 or 3 of aziridine, positions 2, 3, or 4 of azetidine, positions 2, 3, 4, 5, 6, 7, or 8 of quinoline, or positions 1, 3, 4, 5, 6, 7, or 8 of isoquinoline.
[0053] To give an example, though not an exhaustive list, nitrogen-bonded heterocyclic rings or heteroaryls are bound to aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole (position 1), isoindole or isoindoline (position 2), morpholine (position 4), and carbazole or β-carbolin (position 9).
[0054] The terms "halo" and "halogen" refer to fluorine, chlorine, bromine, or iodine atoms, either by themselves or as part of another substituent.
[0055] The term "carbonyl" refers to a carbon atom that, either by itself or as part of another substituent, is double-bonded to oxygen and to two other groups within the carbonyl moiety, namely C(=O) or -C(=O)-.
[0056] As used herein, the term "quaternary ammonium salt" refers to a tertiary amine that has been quaternized with an alkyl substituent (e.g., a C1-C4 alkyl such as methyl, ethyl, propyl, or butyl).
[0057] The terms “to treat,” “to treat,” and “to treat” refer to any sign of success in treating or improving an injury, pathology, disease (e.g., cancer), or symptom (e.g., cognitive impairment), including any objective or subjective parameters such as reduction, remission, relief of symptoms, or making the symptom, injury, pathology, or disease more tolerable for the patient, a decrease in the rate of progression of symptoms, a decrease in the frequency or duration of symptoms or disease, or, in some cases, prevention of the onset of symptoms. Treatment or improvement of symptoms may be based on any objective or subjective parameters, including, for example, the results of a physical examination.
[0058] The terms “cancer,” “neoplasm,” and “tumor” are used herein to refer to cells that exhibit autonomous, uncontrolled growth, such that the cells exhibit an abnormal proliferation phenotype characterized by a marked loss of control over cell proliferation. Cells of interest for detection, analysis, and / or treatment in the context of the present invention include cancer cells (e.g., cancer cells from an individual with cancer), malignant cancer cells, pre-metastatic cancer cells, metastatic cancer cells, and non-metastatic cancer cells. Cancers of virtually all tissues are known. The term “cancer load” refers to the amount or volume of cancer cells in a subject. Therefore, reducing the cancer load refers to reducing the number or volume of cancer cells in a subject. As used herein, the term “cancer cell” refers to a cancer cell (e.g., from any cancer that can be isolated from an individual that can be treated, e.g., an individual with cancer), or any cell derived from a clone of a cancer cell, e.g., a cancer cell. For example, a cancer cell may be from an established cancer cell line, a primary cell isolated from an individual with cancer, or a progeny cell from a primary cell isolated from an individual with cancer. In some embodiments, the term may also refer to a portion of a cancer cell, a subcellular portion of a cancer cell, a cell membrane portion, or a cell lysate. Many types of cancer are known to those skilled in the art, including solid tumors such as carcinoma, sarcoma, glioblastoma, melanoma, lymphoma, and myeloma, as well as circulating cancers such as leukemia.
[0059] As used herein, the term "cancer" includes any form of cancer, including but not limited to solid tumor carcinomas (e.g., skin, lung, prostate, breast, stomach, bladder, colon, ovary, pancreas, kidney, liver, glioblastoma, medulloblastoma, leiomyosarcoma, squamous cell carcinoma of the head and neck, melanoma, and neuroendocrine cancers) and fluid carcinomas (e.g., hematological cancers), carcinomas, soft tissue tumors, sarcomas, deformities, melanomas, leukemias, lymphomas, and brain cancers, including both primary and metastatic tumors, with respect to minimal residual disease.
[0060] The “pathology” of cancer encompasses all phenomena that impair the patient’s well-being. These include, but are not limited to, abnormal or uncontrolled cell proliferation, metastasis, interference with the normal function of adjacent cells, release of cytokines or other secretory products at abnormal levels, suppression or exacerbation of inflammatory or immunological responses, neoplasms, pre-malignant tumors, malignant tumors, and invasion of surrounding or distant tissues or organs, such as lymph nodes.
[0061] As used herein, the terms “cancer recurrence” and “tumor recurrence,” as well as their grammatical variations, refer to further proliferation of neoplastic or cancerous cells following a diagnosis of cancer. In particular, recurrence may occur when further proliferation of cancerous cells occurs in cancerous tissue. Similarly, “tumor diffusion” occurs when tumor cells spread locally or to distant tissues and organs, and therefore tumor diffusion includes tumor metastasis. “Tumor invasion” occurs when tumor growth spreads locally and impairs the function of the tissue involved by compression, destruction, or prevention of normal organ function.
[0062] As used herein, the term “metastasis” refers to the growth of a cancerous tumor in an organ or body part that is not directly connected to the organ of the original cancerous tumor. Metastasis will be understood to include micrometastasis, which is the presence of undetectable amounts of cancer cells in an organ or body part that is not directly connected to the organ of the original cancerous tumor. Metastasis can also be defined as several steps in a process such as the detachment of cancer cells from the original tumor site and the migration and / or invasion of cancer cells to other parts of the body.
[0063] The terms "effective dose" and "therapeutic effective dose" refer to the dosage or amount of a substance, such as an immune complex, that is administered to produce a therapeutic effect. The exact dosage depends on the therapeutic purpose and can be determined by those skilled in the art using known techniques (e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999), Pickar, Dosage Calculations (1999), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11 th Edition (McGraw-Hill, 2006), and The Science and Practice of Pharmacy, 22 nd See Edition, (Pharmaceutical Press, London, 2012). In the case of cancer, a therapeutically effective amount of immune complexes may reduce the number of cancer cells, shrink tumor size, inhibit (i.e., slow, preferably stop) the invasion of cancer cells into peripheral organs, inhibit (i.e., slow, preferably stop) tumor metastasis, inhibit tumor growth to some extent, and / or alleviate to some extent one or more of the symptoms associated with cancer. Insofar as the immune complexes can prevent the proliferation and / or death of existing cancer cells, they may be cell proliferation inhibitory and / or cytotoxic. In the case of cancer treatment, efficacy can be measured, for example, by evaluating the time to disease progression (TTP) and / or determining the response rate (RR).
[0064] The terms “recipient,” “individual,” “subject,” “host,” and “patient” are used interchangeably and refer to any mammalian subject (e.g., human) to whom diagnosis, treatment, or therapy is desired. “Mammal” means any animal classified as a mammal, including humans, domesticated animals, and livestock, as well as zoo animals, sport animals, or pet animals such as dogs, horses, cats, cows, sheep, goats, pigs, and camels. In certain embodiments, the mammal is a human.
[0065] In the context of this invention, the terms “synergistic adjuvant” or “synergistic combination” include combinations of two immunomodulators, such as receptor agonists, cytokines, and adjuvant polypeptides, that, when combined, induce a synergistic effect on immunity compared to the administration of either one alone. In particular, the immune complexes disclosed herein include the claimed synergistic combinations of adjuvants and antibody constructs. These synergistic combinations at administration induce a greater effect on immunity compared, for example, when the antibody construct or adjuvant is administered in the absence of the other part. Furthermore, a reduced amount of the immune complex may be administered (as measured by the total number of antibody constructs or the total number of adjuvants administered as part of the immune complex) compared to when either the antibody construct or the adjuvant is administered alone.
[0066] As used herein, the term “administer” refers to parenteral, intravenous, intraperitoneal, intramuscular, intratumoral, intralesional, intranasal, or subcutaneous administration, oral administration, administration as a suppository, topical contact, intrathecal administration, or implantation of a sustained-release device to a subject, such as a mini osmotic pump.
[0067] Where used herein to modify numerical values, the terms “about” and “approximately” indicate a close range around a numerical value. Thus, if “X” is a value, “about X” or “approximately X” refers to values between 0.9X and 1.1X, e.g., 0.95X and 1.05X or 0.99X and 1.01X. References to “about X” or “approximately X” specifically indicate values of at least X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Therefore, “about X” and “approximately X” are intended to teach and provide written descriptive support for claim limitations, such as “0.98X”.
[0068] HER2 antibody The immunocomplex of the invention comprises an antibody construct containing an antigen-binding domain that specifically recognizes and binds to HER2.
[0069] In certain embodiments, the immune complex of the invention comprises an anti-HER2 antibody. In one embodiment of the invention, the anti-HER2 antibody of the immune complex of the invention comprises humanized anti-HER2 antibodies, e.g., huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7, and huMAb4D5-8, as listed in Table 3 of US5821337, which are specifically and expressly incorporated herein by reference. These antibodies contain a human framework region having a complementarity-determining region of a mouse antibody (4D5) that binds to HER2. The humanized antibody huMAb4D5-8 is also known as trastuzumab and is marketed under the trade name HERCEPTIN® (Genentech, Inc.).
[0070] Trastuzumab (CAS180288-69-1, HERCEPTIN®, huMAb4D5-8, rhuMAb HER2, Genentech) is found to be superior to HER2 extracellular domains in cell-based assays (Kd=5nM). (US5677171, US5821337, US6054297, US6165464, US6339142, US6407213, US6639055, US6719971, US6800738, US7074404, Coussens et al (1985) Science 230:1132-9, Slamon et al (1989) Science 244:707-12, Slamon et al (2001) New This is a recombinant DNA-derived IgG1 kappa monoclonal antibody, a humanized version of the mouse anti-HER2 antibody (4D5) that selectively binds with high affinity to (Engl.J.Med.344:783-792).
[0071] In one embodiment of the invention, the antibody construct or antigen-binding domain comprises the CDR region of trastuzumab. In one embodiment of the invention, the anti-HER2 antibody further comprises the framework region of trastuzumab. In one embodiment of the invention, the anti-HER2 antibody further comprises one or both variable regions of trastuzumab.
[0072] In another embodiment of the invention, the anti-HER2 antibody of the immune complex of the invention comprises a humanized anti-HER2 antibody, such as humanized 2C4, described in US7862817. An exemplary humanized 2C4 antibody is pertuzumab (CAS Reg. No. 380610-27-5), PERJETA™ (Genentech, Inc.). Pertuzumab is a HER dimerization inhibitor (HDI) and functions to inhibit the ability of HER2 to form active hetero- or homodimers with other HER receptors such as EGFR / HER1, HER2, HER3, and HER4. See, for example, Harari and Yarden, Oncogene 19:6102-14 (2000); Yarden and Sliwkowski, Nat Rev Mol Cell Biol 2:127-37 (2001), Sliwkowski Nat Struct Biol 10:158-9 (2003), Cho et al., Nature 421:756-60 (2003), and Malik et al., Pro Am Soc Cancer Res 44:176-7 (2003). PERJETA™ is approved for the treatment of breast cancer.
[0073] In one embodiment of the invention, the antibody construct or antigen-binding domain comprises the CDR regions of pertuzumab. In one embodiment of the invention, the anti-HER2 antibody further comprises the framework regions of pertuzumab. In one embodiment of the invention, the anti-HER2 antibody further comprises one or both of the variable regions of pertuzumab.
[0074] The immune complexes of the invention comprise antibodies that target, bind to, or recognize HER2. The scope of the embodiments of the invention includes functional variants of the antibody constructs or antigen-binding domains described herein. As used herein, the term "functional variant" refers to an antibody construct comprising an antigen-binding domain having substantial or significant sequence identity or similarity to the parental antibody construct or antigen-binding domain, and the functional variant retains the biological activity of the antibody construct or antigen-binding domain of which it is a variant. Functional variants retain, for example, the ability to recognize target cells expressing HER2 to the same extent, to a similar extent, or to a higher extent as the parental antibody construct or antigen-binding domain. Variants of the antibody constructs or antigen-binding domains (parental antibody constructs or antigen-binding domains) described herein are encompassed.
[0075] With respect to an antibody construct or antigen-binding domain, a functional variant can be, for example, at least about 30%, about 50%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more identical to the antibody construct or antigen-binding domain in amino acid sequence.
[0076] Functional variants can comprise, for example, the amino acid sequence of a parental antibody construct or antigen-binding domain having at least one conservative amino acid substitution. Alternatively or additionally, functional variants can comprise the amino acid sequence of a parental antibody construct or antigen-binding domain having at least one non-conservative amino acid substitution. In this case, it is preferred that the non-conservative amino acid substitution does not interfere with or inhibit the biological activity of the functional variant. Non-conservative amino acid substitutions can enhance the biological activity of the functional variant such that the biological activity of the functional variant is increased as compared to the parental antibody construct or antigen-binding domain.
[0077] The antibody containing the immunocomplex of the invention contains Fc-manipulated variants. In some embodiments, the mutations in the Fc region that result in regulated binding to one or more Fc receptors are the following mutations: SD(S239D), SDIE(S239D / I332E), SE(S267E), SELF(S267E / L328F), SDIE(S239D / I332E), SDIEAL(S239D / I332E / A330L), GA(G236A), ALIE(A330L / I332E), GAS DALIE(G236A / S239D / A330L / I332E), V9(G237D / P238D / P271G / A330R), and V11(G237D / P238D / H268D / P271G / A330R) may include one or more mutations in the following amino acids: E345R, E233, G237, P238, H268, P271, L328, and A330. Additional Fc region modifications to modulate Fc receptor binding are described, for example, in U.S. Patent Application No. 2016 / 0145350 and U.S. Patents No. 7,416,726 and No. 5,624,821, which are incorporated herein by reference in their entirety.
[0078] The antibody containing the immunocomplex of the invention includes glycosylation variants such as afucosylation. In some embodiments, the Fc region of the binder is modified to have an altered glycosylation pattern compared to the natural, unmodified Fc region.
[0079] The amino acid substitutions in the antibody construct or antigen-binding domain of the present invention are preferably conservative amino acid substitutions. Conservative amino acid substitutions include those known in the art in which one amino acid having certain physical and / or chemical properties is replaced with another amino acid having the same or similar chemical or physical properties. For example, conservative amino acid substitutions may include acidic / loading electrode amino acids substituted with other acidic / loading electrode amino acids (e.g., Asp or Glu), amino acids with nonpolar side chains substituted with other amino acids having nonpolar side chains (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.), basic / positively loaded electrode amino acids substituted with other basic / positively loaded electrode amino acids (e.g., Lys, His, Arg, etc.), uncharged amino acids with polar side chains substituted with other uncharged amino acids having polar side chains (e.g., Asn, Gln, Ser, Thr, Tyr, etc.), amino acids with beta-branched side chains substituted with other amino acids having beta-branched side chains (e.g., Ile, Thr, and Val), and amino acids with aromatic side chains substituted with other amino acids having aromatic side chains (e.g., His, Phe, Trp, and Tyr).
[0080] The antibody construct or antigen-binding domain may essentially consist of a sequence of one of the specified amino acid sequences described herein, and as a result, other components, such as other amino acids, do not substantially alter the biological activity of the antibody construct or antigen-binding domain functional variant.
[0081] In some embodiments, the antibody in the immune complex contains a modified Fc region, and the modification modulates the binding of the Fc region to one or more Fc receptors.
[0082] In some embodiments, the antibody in the immune complex (e.g., an antibody conjugated to at least two adjuvant moieties) contains one or more modifications within the Fc region (e.g., amino acid insertions, deletions, and / or substitutions) that result in regulated binding (e.g., increased or decreased binding) to one or more Fc receptors (e.g., FcγRI(CD64), FcγRIIA(CD32A), FcγRIIB(CD32B), FcγRIIIA(CD16a), and / or FcγRIIIB(CD16b)) compared to a native antibody lacking mutations within the Fc region. In some embodiments, the antibody in the immune complex contains one or more modifications within the Fc region (e.g., amino acid insertions, deletions, and / or substitutions) that reduce the binding of the antibody's Fc region to FcγRIIB. In some embodiments, the antibody in the immunocomplex contains one or more modifications within the Fc region of the antibody (e.g., amino acid insertions, deletions, and / or substitutions) that reduce the binding of the antibody to FcγRIIB while maintaining or increasing the binding to FcγRI(CD64), FcγRIIA(CD32A), and / or FcRγIIIA(CD16a) compared to a native antibody lacking mutations within the Fc region. In some embodiments, the antibody in the immunocomplex contains one or more modifications within the Fc region that increase the binding of the antibody's Fc region to FcγRIIB.
[0083] In some embodiments, regulated binding is provided by mutations within the antibody's Fc region compared to the antibody's native Fc region. The mutations may be in the CH2 domain, the CH3 domain, or a combination thereof. “Natural Fc region” is synonymous with “wild-type Fc region” and includes an amino acid sequence that is identical to the amino acid sequence of a naturally occurring Fc region or identical to the amino acid sequence of a naturally occurring antibody (e.g., cetuximab). Examples of naturally occurring human Fc regions include the natural human IgG1Fc region, the natural human IgG2Fc region, the natural human IgG3Fc region, and the natural human IgG4Fc region, as well as their naturally occurring variants. Natural Fc includes various allotypes of Fc (Jefferis et al., (2009) mAbs, 1(4):332-338).
[0084] In some embodiments, mutations in the Fc region that result in regulated binding to one or more Fc receptors include the following mutations: SD(S239D), SDIE(S239D / I332E), SE(S267E), SELF(S267E / L328F), SDIE(S239D / I332E), SDIEAL(S239D / I332E / A330L), GA(G236A), ALIE(A330L / I332E), GASDALIE(G236A / S239D / A330L / I332E), V9(G237D / P238D / P271G / A330R), and V11(G237D / P238D / H268D / P271G / A330R) may contain one or more mutations in the following amino acids: E233, G237, P238, H268, P271, L328, and A330. Additional Fc region modifications to modulate Fc receptor binding are described, for example, in US2016 / 0145350, US7416726, and US5624821, which are incorporated herein by reference in their entirety.
[0085] In some embodiments, the Fc region of the antibody in the immunocomplex is modified to have an altered glycosylation pattern compared to the native, unmodified Fc region.
[0086] Human immunoglobulins are glycosylated at the Asn297 residue within the Cγ2 domain of each heavy chain. This N-linked oligosaccharide consists of a coreheptasaccharide and N-acetylglucosamine 4-mannose 3 (GlcNAc4Man3). Removal of the heptasaccharide by endoglycosidase or PNGase F is known to result in structural changes in the antibody Fc region, which can significantly reduce antibody binding affinity to FcγR activation and impair effector function. Coreheptasaccharides are often modified with galactose, bifacial GlcNAc, fucose, or sialic acid, which differentially affect Fc binding to activating and inhibitory FcγR. Furthermore, α2,6-sialylation has been shown to enhance anti-inflammatory activity in vivo, while defucosylation has been demonstrated to improve FcγRIIIa binding, as well as a tenfold increase in antibody-dependent cytotoxicity and antibody-dependent phagocytosis. Therefore, inflammatory effector function can be controlled using specific glycosylation patterns.
[0087] In some embodiments, the modification for altering the glycosylation pattern is a mutation, for example, a substitution at Asn297. In some embodiments, Asn297 is mutated to glutamine (N297Q). Methods for controlling immune responses by antibodies that modulate FcγR regulatory signaling are described, for example, in U.S. Patent No. 7,416,726 and U.S. Patent Application Publications 2007 / 0014795 and 2008 / 0286819, which are incorporated herein by reference in their entirety.
[0088] In some embodiments, the antibodies of the immunocomplex are modified to contain an engineered Fab region having a glycosylation pattern not found in nature. For example, hybridomas can be genetically engineered to secrete afucosylated mAb, deallylated mAb, or deglycosylated Fc with specific mutations that enable increased FcRγIIIa binding and effector function. In some embodiments, the antibodies of the immunocomplex are engineered to be afucosylated.
[0089] In some embodiments, the entire Fc region of the antibody within the immune complex is replaced with a different Fc region, resulting in the Fab region of the antibody being conjugated with a non-natural Fc region. In some embodiments, the Fc-modified antibody having a non-natural Fc domain also includes one or more amino acid modifications, such as the S228P mutation in IgG4Fc, which modulate the stability of the described Fc domain. In some embodiments, the Fc-modified antibody having a non-natural Fc domain also includes one or more amino acid modifications described herein that modulate Fc binding to FcR.
[0090] In some embodiments, modifications that modify the binding of the Fc region to FcR do not alter the binding of the antibody's Fab region to its antigen compared to a naturally occurring unmodified antibody. In other embodiments, modifications that modify the binding of the Fc region to FcR also increase the binding of the antibody's Fab region to its antigen compared to a naturally occurring unmodified antibody.
[0091] In some embodiments, the antibodies in the immune complex are glycosylated.
[0092] In some embodiments, the antibody in the immune complex is a cysteine-manipulated antibody that provides site-specific conjugation of an adjuvant, label, or drug moiety via cysteine substitution at a site that does not disrupt immunoglobulin folding and assembly, or antigen binding and effector function (Junutula, et al., 2008b Nature Biotech., 26(8):925-932, Dornan et al. (2009) Blood 114(13):2721-2729, US7521541, US7723485, US2012 / 0121615, WO2009 / 052249). A "cysteine-manipulated antibody" or "cysteine-manipulated antibody variant" is an antibody in which one or more residues of the antibody are substituted with cysteine residues. Cysteine-manipulated antibodies can be conjugated to the 8-Phe-2-aminobenzazepine adjuvant moiety as an 8-phenyl-2-aminobenzazepine linker compound with a homogeneous stoichiometry (for example, up to two 8-Phe-2-aminobenzazepine moieties per antibody in an antibody with a single manipulated cysteine moiety).
[0093] In some embodiments, the cysteine-modified antibody used to prepare the immunocomplexes shown in Table 3 has a cysteine residue introduced at the 149-lysine site (LC K149C) of the light chain. In other embodiments, the cysteine-modified antibody has a cysteine residue introduced at the 118-alanine site (EU numbering) (HC A118C) of the heavy chain. This site is alternatively numbered 121 by sequential numbering or 114 by Kabat numbering. In other embodiments, the cysteine-modified antibody has a cysteine residue introduced at the light chain G64C or R142C by Kabat numbering, or at the heavy chain D101C, V184C, or T205C by Kabat numbering.
[0094] 8-phenyl-2-aminobenzazepine adjuvant compounds The immune complex of the present invention comprises an 8-Phe-2-aminobenzazepine adjuvant moiety. The adjuvant moiety described herein is a compound that induces an immune response (i.e., an immunostimulant). Generally, the adjuvant moiety described herein is a TLR agonist. TLRs are type I transmembrane proteins involved in the initiation of innate immune responses in vertebrates. TLRs recognize various pathogen-associated molecular patterns from bacteria, viruses, and fungi and function as the first line of defense against invading pathogens. TLRs induce overlapping but distinct biological responses due to differences in cellular expression and the signaling pathways they initiate. When engaged (e.g., by innate stimuli or synthetic TLR agonists), TLRs initiate a signaling cascade that leads to the activation of nuclear factor-κB (NF-κB) and the recruitment of IL-1 receptor-associated kinase (IRAK) via the adapter protein myeloid differentiation primary response gene 88 (MyD88). Subsequently, phosphorylation of IRAK leads to the recruitment of TNF-receptor-associated factor 6 (TRAF6), which results in the phosphorylation of the NF-κB inhibitor I-κB. As a result, NF-κB enters the cell nucleus and initiates transcription of genes with promoters containing NF-κB binding sites, such as cytokines. Additional regulatory modes for TLR signaling include TIR domain-containing adapter-induced interferon-beta (TRIF)-dependent induction of TNF-receptor-associated factor 6 (TRAF6), as well as activation of the MyD88 independent pathway via TRIF and TRAF3, leading to the phosphorylation of interferon-response factor 3 (IRF3). Similarly, the MyD88-dependent pathway also activates several IRF family members, including IRF5 and IRF7, while the TRIF-dependent pathway also activates the NF-κB pathway.
[0095] Typically, the adjuvant moiety described herein is a TLR7 and / or TLR8 agonist. Both TLR7 and TLR8 are expressed in monocytes and dendritic cells. In humans, TLR7 is also expressed in plasmacytoid dendritic cells (pDCs) and B cells. TLR8 is mainly expressed in cells of myeloid origin, namely monocytes, granulocytes, and myeloid dendritic cells. TLR7 and TLR8 can detect the presence of intracellular "foreign" single-stranded RNA as a means of responding to viral invasion. Treatment of TLR8-expressing cells with a TLR8 agonist can result in the production of high levels of IL-12, IFN-γ, IL-1, TNF-α, IL-6, and other inflammatory cytokines. Similarly, stimulation of TLR7-expressing cells, such as pDCs, with a TLR7 agonist can result in the production of high levels of IFN-α and other inflammatory cytokines. TLR7 / TLR8 involvement and the resulting cytokine production can activate dendritic cells and other antigen-presenting cells and drive diverse innate and acquired immune response mechanisms leading to tumor destruction.
[0096] Exemplary 8-phenyl-2-aminobenzazepine compounds (PhBz) of the invention are shown in Table 1. Each compound was synthesized, purified, characterized by mass spectrometry, and shown to have the indicated mass. Additional experimental procedures can be found in the Examples. Activity against HEK293 NFKB reporter cells expressing human TLR7 or human TLR8 was measured according to Example 202. The 8-phenyl-2-aminobenzazepine compounds in Table 1 demonstrate surprising and unexpected properties of TLR8 agonist selectivity that can predict useful therapeutic activity for treating cancer and other disorders.
Table 1-1
Table 1-2
Table 1-3
Table 1-4
[0097] 8-phenyl-2-aminobenzazepine-linker compound The immune complex of the present invention is prepared by conjugation of an anti-HER2 antibody with an 8-phenyl-2-aminobenzazepine-linker compound, PhBzL. The 8-phenyl-2-aminobenzazepine-linker compound contains an 8-Phe-2-aminobenzazepine (PhBz) moiety covalently bonded to a linker unit. The linker unit contains functional groups and subunits that affect the stability, permeability, solubility, and other pharmacokinetic, safety, and efficacy properties of the immune complex. The linker unit contains reactive functional groups that react with, i.e., conjugate with, the reactive functional groups of the antibody. For example, nucleophilic groups such as the lysine side chain amino of the antibody react with the electrophilic reactive functional groups of the PhBzL linker compound to form the immune complex. Alternatively, for example, cysteinethiol of the antibody reacts with the maleimide or bromoacetamide group of the Hx-linker compound to form the immune complex.
[0098] Suitable electrophilic functional groups for PhBzL linker compounds include, but are not limited to, N-hydroxysuccinimidyl (NHS) esters and N-hydroxysulfosuccinimidyl (sulfo-NHS) esters (amine-reactive), carbodiimide (amine and carboxyl-reactive), hydroxymethylphosphine (amine-reactive), maleimide (thiol-reactive), halogenated acetamides such as N-iodoacetamide (thiol-reactive), aryl azides (primary amine-reactive), fluorinated aryl azides (reactive via carbon-hydrogen (CH) insertion), pentafluorophenyl (PFP) esters (amine-reactive), terafluorophenyl (TFP) esters (amine-reactive), imide esters (amine-reactive), isocyanates (hydroxyl-reactive), vinyl sulfones (thiol, amine, and hyphoroxyl-reactive), pyridyl disulfide (thiol-reactive), and benzophenone derivatives (reactive via CH bond insertion). Further reagents can be found in Hermanson, Bioconjugate Techniques 2. nd This list includes, but is not limited to, those listed in Edition, Academic Press, 2008.
[0099] This invention provides solutions to limitations and challenges in the design, preparation, and use of immune complexes. Some linkers can be unstable in the bloodstream, thereby releasing unacceptable amounts of adjuvant / drug before internalization in target cells (Khot, A. et al (2015) Bioanalysis 7(13):1633-1648). Other linkers may provide stability in the bloodstream, but intracellular release efficacy may be negatively affected. Linkers that provide the desired intracellular release typically have low stability in the bloodstream. In other words, bloodstream stability and intracellular release are typically inversely correlated. Furthermore, in a standard conjugation process, the amount of adjuvant / drug moiety loaded onto the antibody, i.e., the amount of drug loading, the amount of aggregates formed in the conjugation reaction, and the yield of the final purified complex that may be obtained are interrelated. For example, aggregate formation is generally positively correlated with the number of adjuvant / drug moieties and their derivative equivalents conjugated to the antibody. Under high drug loads, the aggregates formed must be removed for therapeutic use. Consequently, the formation of drug-load-mediated aggregates can reduce immune complex yields and make process scaling difficult.
[0100] An exemplary embodiment is shown in Formula II: [ka] The compound comprises an 8-phenyl-2-aminobenzazepine-linker compound, where R 1 , R 2 , R 3 , and R 4 However, independently, H, C1-C 12 Alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Carbocyclyl, C6-C 20 Aryl, C2-C9 heterocyclyl, and C1-C 20 Selected from the group consisting of heteroaryls, where alkyl, alkenyl, alkynyl, carbocykrill, aryl, heterocyclyl, and heteroaryl are independently and arbitrarily selected. -(C1-C12 Alkyldiyl)-N(R 5 )-*, -(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C1-C 12 Alkyldiyl)-OR 5 , -(C3-C 12 Carbocyclyl) -(C3-C 12 Carbocyclyl)-*, -(C3-C 12 Carbocyclyl)-(C1-C 12 Alkyldiyl)-NR 5 -*, -(C3-C 12 Carbocyclyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C3-C 12 Carbocyclil)-NR 5 -C(=NR 5 )NR 5 -*, -(C6-C 20 Ariel), -(C6-C 20 Ariel)-*, -(C6-C 20 Arylzyl)-N(R 5 )-*, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-(C2-C 20 Heterocyclyldiyl)-*, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-NR5 -C(=NR 5a )N(R 5 )-*、 -(C2-C 20 heterocyclic)-、 -(C2-C 20 heterocyclic)-*、 -(C2-C9 heterocyclic)-(C1-C 12 alkyldiyl)-NR 5 -*、 -(C2-C9 heterocyclic)-(C1-C 12 alkyldiyl)-N(R 5 )2、 -(C2-C9 heterocyclic)-C(=O)-(C1-C 12 alkyldiyl)-N(R 5 )-*、<000103-(C1-C 20 Heteroaryl)-N(R 5 )C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -C(=O)-*, -C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -C(=O)-(C2-C 20 Heterocyclyldiyl)-*, -C(=O)N(R 5 )2, -C(=O)N(R 5 )-*, -C(=O)N(R 5 )-(C1-C 12 Alkyldiyl)-N(R 5 )C(=O)R 5 , -C(=O)N(R 5 )-(C1-C 12 Alkyldiyl)-N(R 5 )C(=O)N(R 5 )2, -C(=O)NR 5 -(C1-C 12 Alkyldiyl)-N(R 5 )CO2R 5 , -C(=O)NR 5 -(C1-C 12 Alkyldiyl)-N(R 5 )C(=NR 5a )N(R 5 )2, -C(=O)NR 5 -(C1-C 12 Alkyldiyl)-NR 5 C(=NR 5a )R 5 , -C(=O)NR 5 -(C1-C8 alkyldiyl)-NR 5 (C2-C5 heteroaryl) -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-N(R5 )-*, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-*, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-(C2-C 20 Heterocyclyl(C)(=O)NR 5 -(C1-C 12 Alkyldiyl)-NR 5 -*, -N(R 5 )2, -N(R 5 )-*, -N(R 5 )C(=O)R 5 , -N(R 5 )C(=O)-*, -N(R 5 )C(=O)N(R 5 )2, -N(R 5 )C(=O)N(R 5 )-*, -N(R 5 )CO2R 5 , -NR 5 C(=NR 5a )N(R 5 )2, -NR 5 C(=NR 5a )N(R 5 )-*, -NR 5 C(=NR 5a )R 5 , -N(R 5 )C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -N(R 5 )-(C2-C5 heteroaryl), -N(R 5 )-S(=O)2-(C1-C 12 Alkyl), -O-(C1-C 12 Alkyl), -O-(C1-C 12 Alkyldiyl)-N(R 5 )2, -O-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -OC(=O)N(R 5 )2, -OC(=O)N(R 5 )-*, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-*, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Alkyldiyl)-NR 5 -*, and -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Substituted with one or more groups selected from alkyldiyl)-OH, or R 2 and R 3 Together they form a 5-membered or 6-membered heterocyclyl ring. X 1 , X 2 , X 3 , and X 4 However, independently, they bond, C(=O), C(=O)N(R) 5 ), O, N(R 5 ), S, S(O)2, and S(O)2N(R 5 Selected from the group consisting of, R 5 However, independently, H, C6-C 20 Ariel, C3-C 12 Carbocyclyl, C6-C20 Alylzil, C1-C 12 Alkyl and C1-C 12 Selected from the group consisting of alkyldiyl, or two R 5 The groups together form a 5-membered or 6-membered heterocyclyl ring. R 5a However, C6-C 20 Aryl and C1-C 20 Selected from the group consisting of heteroaryls, In the formula, the asterisk * indicates the binding site of L, and R 1 , R 2 , R 3 , and R 4 One of them is bonded to L, L, QC(=O)-PEG-, QC(=O)-PEG-C(=O)N(R 6 )-(C1-C 12 Alkyldiyl)-C(=O)-Gluc-, QC(=O)-PEG-O-, QC(=O)-PEG-OC(=O)-, QC(=O)-PEG-C(=O)-, QC(=O)-PEG-C(=O)-PEP-, QC(=O)-PEG-N(R 6 )-, QC(=O)-PEG-N(R 6 )-C(=O)-, QC(=O)-PEG-N(R 6 )-PEG-C(=O)-PEP-, QC(=O)-PEG-N + (R 6 )2-PEG-C(=O)-PEP-, QC(=O)-PEG-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, QC(=O)-PEG-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)N(R 6)C(=O)-(C2-C5 monoheterocyclyldiyl)-, QC(=O)-PEG-SS-(C1-C 12 Alkyldiyl)-OC(=O)-, QC(=O)-PEG-SS-(C1-C 12 Alkyldiyl)-C(=O)-, QC(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-, QC(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, QC(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-N(R 5 )-C(=O), QC(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-N(R 6 )C(=O)-(C2-C5 monoheterocyclyldiyl)-, Q-(CH2) m -C(=O)N(R 6 )-PEG-, Q-(CH2) m -C(=O)N(R 6 )-PEG-C(=O)N(R 6 )-(C1-C 12 Alkyldiyl)-C(=O)-Gluc-, Q-(CH2) m -C(=O)N(R 6 )-PEG-O-, Q-(CH2) m -C(=O)N(R 6 )-PEG-OC(=O)-, Q-(CH2) m -C(=O)N(R 6 )-PEG-C(=O)-, Q-(CH2)m -C(=O)N(R 6 )-PEG-N(R 5 )-, Q-(CH2) m -C(=O)N(R 6 )-PEG-N(R 5 )-C(=O)-, Q-(CH2) m -C(=O)N(R 6 )-PEG-C(=O)-PEP-, Q-(CH2) m -C(=O)N(R 6 )-PEG-SS-(C1-C 12 Alkyldiyl)-OC(=O)-, Q-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, Q-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)N(R 6 )C(=O)-, and Q-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)N(R 6 A linker selected from the group consisting of )C(=O)-(C2-C5 monoheterocyclyldiyl), R 6 However, independently, they are H or C1-C6 alkyl, PEG is given by the formula: -(CH2CH2O) n -(CH2) m It has -, where m is an integer from 1 to 5, and n is an integer from 2 to 50. Gluc, formula: [ka] It has, PEP is, formula: [ka] The formula has such that AA is independently selected from natural or unnatural amino acid side chains, or one or more AAs and adjacent nitrogen atoms form a 5-membered proline amino acid ring, and the wavy lines indicate bonding points. Cyc is optionally substituted with one or more groups selected from F, Cl, NO2, -OH, -OCH3, and glucuronic acid having the following structures, C6-C 20 Aryl silicone and C1-C 20 Selected from heteroaryldiyls, [ka] R 7 However, -CH(R 8 )O-, -CH2-, -CH2N(R 8 )-, and -CH(R 8 Selected from the group consisting of )OC(=O)-, in the formula, R 8 However, H, C1-C6 alkyl, C(=O)-C1-C6 alkyl, and -C(=O)N(R 9 ) Selected from 2, in the formula, R 9 However, independently, H, C1-C 12 Alkyl and -(CH2CH2O) n -(CH2) m Selected from the group consisting of -OH, where m is an integer from 1 to 5, n is an integer from 2 to 50, or two R 9 The groups together form a 5-membered or 6-membered heterocyclyl ring. y is an integer between 2 and 12. z is 0 or 1, Q is F, Cl, NO2, and SO3 - A group selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxysulfosuccinimidyl, maleimide, and phenoxy, which is substituted with one or more groups independently selected from the above. Alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyryl, carbocyryldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally selected as F, Cl, Br, I, -CN, -CH3, -CH2CH3, -CH=CH2, -C≡CH, -C≡CCH3, -C H2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2OH, -CH2OCH3, -CH2CH2OH, -C(CH3)2OH, -CH(OH)CH(CH3)2, -C(CH3 )2CH2OH, -CH2CH2SO2CH3, -CH2OP(O)(OH)2, -CH2F, -CHF2, -CF3, -CH2CF3, -CH2CHF2, -CH(CH3)CN, -C(CH3)2C N, -CH2CN, -CH2NH2, -CH2NHSO2CH3, -CH2NHCH3, -CH2N(CH3)2, -CO2H, -COCH3, -CO2CH3, -CO2C(CH3)3, -COCH (OH)CH3, -CONH2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3 , -NHS(O)2CH3, -N(CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3, -NHC(=NH)H, -NHC(=NH)CH3, -NHC(=NH)NH2 , -NHC(=O)NH2, -NO2, =O, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH2CH2OH, -OCH2CH2N(CH3)2, -O(CH2CH2O) n -(CH2) m CO2H, -O(CH2CH2O) n Substituted with one or more groups independently selected from H, -OCH2F, -OCHF2, -OCF3, -OP(O)(OH)2, -S(O)2N(CH3)2, -SCH3, -S(O)2CH3, and -S(O)3H.
[0101] An exemplary embodiment of the 8-phenyl-2-aminobenzazepine-linker compound of formula II is that Q is [ka] This includes being selected from.
[0102] Exemplary embodiments of the 8-phenyl-2-aminobenzazepine-linker compounds of formula II include a phenoxy compound in which Q is substituted with one or more Fs.
[0103] Exemplary embodiments of the 8-phenyl-2-aminobenzazepine-linker compound of formula II include Q being 2,3,5,6-tetrafluorophenoxy.
[0104] Exemplary embodiments of the 8-phenyl-2-aminobenzazepine-linker (PhBzL) compounds are selected from Tables 2a and 2b. Each compound was synthesized, purified, and characterized by mass spectrometry, and was shown to have the indicated mass. Additional experimental procedures are described in the Examples. The 8-phenyl-2-aminobenzazepine-linker compounds of Table 2 demonstrate surprising and unexpected properties of TLR8 agonist selectivity, which may predict useful therapeutic activity for treating cancer and other disorders. The 8-phenyl-2-aminobenzazepine-linker intermediates of Formula II from Tables 2a and 2b were used to form the immunocomplexes of Tables 3a and 3b by conjugating them with antibodies by the method of Example 201. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] Table 2-8 Table 2-9 Table 2-10 Table 2-11 Table 2-12 Table 2-13 Table 2-14 Table 2-15 Table 2-16 Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 3-1 [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11]
[0105] immune complex An exemplary embodiment of the immune complex comprises an anti-HER2 antibody covalently bound to one or more 8-Phe-2-aminobenzazepine (PhBz) moieties by a linker, and formula I: Ab-[L-PhBz] p I It has, During the ceremony, Ab is an antibody construct having an antigen-binding domain that binds to HER2. p is an integer between 1 and 8. PhBz is, formula: [ka] The 8-phenyl-2-aminobenzazepine moiety has R 1 , R 2 , R 3 , and R 4 However, independently, H, C1-C 12 Alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C 12 Carbocyclyl, C6-C 20 Aryl, C2-C9 heterocyclyl, and C1-C 20 Selected from the group consisting of heteroaryls, where alkyl, alkenyl, alkynyl, carbocykrill, aryl, heterocyclyl, and heteroaryl are independently and arbitrarily selected. -(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C1-C 12 Alkyldiyl)-OR 5 , -(C3-C 12 Carbocyclyl) -(C3-C 12 Carbocyclyl)-*, -(C3-C 12 Carbocyclyl)-(C1-C 12 Alkyldiyl)-NR 5 -*, -(C3-C 12 Carbocyclyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C3-C 12 Carbocyclil)-NR 5 -C(=NR 5 )NR 5 -*, -(C6-C 20 Ariel), -(C6-C 20 Ariel)-*, -(C6-C 20 Arylzyl)-N(R 5 )-*, -(C6-C20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-(C2-C 20 Heterocyclyldiyl)-*, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-NR 5 -C(=NR 5a )N(R 5 )-*, -(C2-C 20 Heterocycline), -(C2-C 20 Heterocyclyl)-*, -(C2-C9 heterocyclyl)-(C1-C 12 Alkyldiyl)-NR 5 -*, -(C2-C9 heterocyclyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C2-C9 heterocyclyl)-C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C2-C9 heterocyclyl)-NR 5 -C(=NR 5a )NR 5 -*, -(C2-C9 heterocyclyl)-NR 5 -(C6-C 20 (Alyl-Jil)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C2-C9 heterocyclyl)-(C6-C 20 Aryljil)-*, -(C1-C 20 (heteroaryl), -(C1-C 20 Heteroaryl)-*, -(C1-C 20 Heteroaryl)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -(C1-C 20 Heteroaryl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -(C1-C 20 Heteroaryl)-NR 5 -C(=NR 5a )N(R 5 )-*, -(C1-C 20 Heteroaryl)-N(R 5 )C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -C(=O)-*, -C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -C(=O)-(C2-C 20 Heterocyclyldiyl)-*, -C(=O)N(R 5 )2, -C(=O)N(R 5 )-*, -C(=O)N(R 5 )-(C1-C 12 Alkyldiyl)-N(R 5 )C(=O)R 5 , -C(=O)N(R 5 )-(C1-C 12 Alkyldiyl)-N(R 5 )C(=O)N(R 5 )2, -C(=O)NR 5 -(C1-C 12 Alkyldiyl)-N(R 5 )CO2R 5 , -C(=O)NR 5 -(C1-C 12Alkyldiyl)-N(R 5 )C(=NR 5a )N(R 5 )2, -C(=O)NR 5 -(C1-C 12 Alkyldiyl)-NR 5 C(=NR 5a )R 5 , -C(=O)NR 5 -(C1-C8 alkyldiyl)-NR 5 (C2-C5 heteroaryl) -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-N(R 5 )-*, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-*, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -C(=O)NR 5 -(C1-C 20 Heteroaryldiyl)-(C2-C 20 Heterocyclyl(C)(=O)NR 5 -(C1-C 12 Alkyldiyl)-NR 5 -*, -N(R 5 )2, -N(R 5 )-*, -N(R 5 )C(=O)R 5 , -N(R 5 )C(=O)-*, -N(R 5 )C(=O)N(R 5 )2, -N(R 5 )C(=O)N(R 5 )-*, -N(R 5 )CO2R 5 , -NR 5 C(=NR 5a )N(R 5 )2, -NR 5 C(=NR 5a )N(R 5 )-*, -NR 5 C(=NR 5a )R 5 , -N(R 5 )C(=O)-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -N(R 5 )-(C2-C5 heteroaryl), -N(R 5 )-S(=O)2-(C1-C 12 Alkyl), -O-(C1-C 12 Alkyl), -O-(C1-C 12 Alkyldiyl)-N(R 5 )2, -O-(C1-C 12 Alkyldiyl)-N(R 5 )-*, -OC(=O)N(R 5 )2, -OC(=O)N(R 5 )-*, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-*, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Alkyldiyl)-N(R 5 )2, -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Alkyldiyl)-NR 5 -*, and -S(=O)2-(C2-C 20 Heterocyclyldiyl)-(C1-C 12 Substituted with one or more groups selected from alkyldiyl)-OH, or R 2 and R 3 Together they form a 5-membered or 6-membered heterocyclyl ring. X 1 , X 2 , X 3 , and X 4 However, independently, they bond, C(=O), C(=O)N(R) 5 ), O, N(R 5 ), S, S(O)2, and S(O)2N(R 5 Selected from the group consisting of, R 5 However, independently, H, C6-C 20 Ariel, C3-C 12 Carbocyclyl, C6-C 20 Alylzil, C1-C 12 Alkyl and C1-C 12 Selected from the group consisting of alkyldiyl, or two R 5 The groups together form a 5-membered or 6-membered heterocyclyl ring. R 5a However, C6-C 20 Aryl and C1-C 20 Selected from the group consisting of heteroaryls, In the formula, the asterisk * indicates the binding site of L, and R 1 , R 2 , R 3 , and R 4 One of them is bonded to L, L, -C(=O)-PEG-, -C(=O)-PEG-C(=O)N(R 6 )-(C1-C 12 Alkyldiyl)-C(=O)-Gluc-, -C(=O)-PEG-O-, -C(=O)-PEG-OC(=O)-, -C(=O)-PEG-C(=O)-, -C(=O)-PEG-C(=O)-PEP-, -C(=O)-PEG-N(R 6 )-, -C(=O)-PEG-N(R 6 )-C(=O)-, -C(=O)-PEG-N(R 6 )-PEG-C(=O)-PEP-, -C(=O)-PEG-N + (R 6 )2-PEG-C(=O)-PEP-, -C(=O)-PEG-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, -C(=O)-PEG-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)N(R 6 )C(=O)-(C2-C5 monoheterocyclyldiyl)-, -C(=O)-PEG-SS-(C1-C 12 Alkyldiyl)-OC(=O)-, -C(=O)-PEG-SS-(C1-C 12 Alkyldiyl)-C(=O)-, -C(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-, -C(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, -C(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-N(R 5 )-C(=O), -C(=O)-(C1-C 12 Alkyldiyl)-C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-N(R 6 )C(=O)-(C2-C5 monoheterocyclyldiyl)-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-, -Sukushinimijil-(CH2) m-C(=O)N(R 6 )-PEG-C(=O)N(R 6 )-(C1-C 12 Alkyldiyl)-C(=O)-Gluc-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-O-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-OC(=O)-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-C(=O)-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-N(R 5 )-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-N(R 5 )-C(=O)-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-C(=O)-PEP-, -Sukushinimijil-(CH2) m -C(=O)N(R 6 )-PEG-SS-(C1-C 12 Alkyldiyl)-OC(=O)-, -Sukushinimijil-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)-, -Sukushinimijil-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12 Alkyldiyl)N(R 6 )C(=O)-, and -Sukushinimijil-(CH2) m -C(=O)-PEP-N(R 6 )-(C1-C 12Alkyldiyl)N(R 6 A linker selected from the group consisting of )C(=O)-(C2-C5 monoheterocyclyldiyl), R 6 However, independently, they are H or C1-C6 alkyl, PEG is given by the formula: -(CH2CH2O) n -(CH2) m It has -, where m is an integer from 1 to 5, and n is an integer from 2 to 50. Gluc, formula: [ka] It has, PEP is, formula: [ka] The formula has such that AA is independently selected from natural or unnatural amino acid side chains, or one or more AAs and adjacent nitrogen atoms form a 5-membered proline amino acid ring, and the wavy lines indicate bonding points. Cyc is optionally substituted with one or more groups selected from F, Cl, NO2, -OH, -OCH3, and glucuronic acid having the following structures, C6-C 20 Aryl silicone and C1-C 20 Selected from heteroaryldiyls, [ka] R 7 However, -CH(R 8 )O-, -CH2-, -CH2N(R 8 )-, and -CH(R 8 Selected from the group consisting of )OC(=O)-, in the formula, R 8 However, H, C1-C6 alkyl, C(=O)-C1-C6 alkyl, and -C(=O)N(R 9 ) Selected from 2, in the formula, R 9 However, independently, H, C1-C 12 Alkyl and -(CH2CH2O) n -(CH2) mSelected from the group consisting of -OH, where m is an integer from 1 to 5, n is an integer from 2 to 50, or two R 9 The groups together form a 5-membered or 6-membered heterocyclyl ring. y is an integer between 2 and 12. z is 0 or 1, Alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyryl, carbocyryldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally selected as F, Cl, Br, I, -CN, -CH3, -CH2CH3, -CH=CH2, -C≡CH, -C≡CCH3, -C H2CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2OH, -CH2OCH3, -CH2CH2OH, -C(CH3)2OH, -CH(OH)CH(CH3)2, -C(CH3 )2CH2OH, -CH2CH2SO2CH3, -CH2OP(O)(OH)2, -CH2F, -CHF2, -CF3, -CH2CF3, -CH2CHF2, -CH(CH3)CN, -C(CH3)2C N, -CH2CN, -CH2NH2, -CH2NHSO2CH3, -CH2NHCH3, -CH2N(CH3)2, -CO2H, -COCH3, -CO2CH3, -CO2C(CH3)3, -COCH (OH)CH3, -CONH2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3 , -NHS(O)2CH3, -N(CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3, -NHC(=NH)H, -NHC(=NH)CH3, -NHC(=NH)NH2 , -NHC(=O)NH2, -NO2, =O, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH2CH2OH, -OCH2CH2N(CH3)2, -O(CH2CH2O) n -(CH2) m CO2H, -O(CH2CH2O) nSubstituted with one or more groups independently selected from H, -OCH2F, -OCHF2, -OCF3, -OP(O)(OH)2, -S(O)2N(CH3)2, -SCH3, -S(O)2CH3, and -S(O)3H.
[0106] Exemplary embodiments of the immune complex of Formula I include the antibody being selected from trastuzumab and pertuzumab, or their biosimilars or biobetters.
[0107] An exemplary embodiment of the immune complex of formula I is X 2 However, it is a bond, R 2 However, this includes being a C1-C8 alkyl group.
[0108] An exemplary embodiment of the immune complex of formula I is X 2 and X 3 However, each is a combination, R 2 and R 3 However, independently, C1-C8 alkyl, -O-(C1-C 12 Alkyl), -(C1-C 12 Alkyldiyl)-OR 5 -(C1-C8 alkyldiyl)-N(R 5 )CO2R 5 ,-(C1-C 12 Alkyl)-OC(O)N(R 5 )2, -O-(C1-C 12 Alkyl)-N(R 5 )CO2R 5 , and -O-(C1-C 12 Alkyl)-OC(O)N(R 5 ) This includes being selected from 2.
[0109] An exemplary embodiment of the immune complex of formula I is R 2 However, it is a C1-C8 alkyl group, and R 3 However, -(C1-C8 alkyldiyl)-N(R 5 )CO2R 5 This includes being.
[0110] An exemplary embodiment of the immune complex of formula I is R 2However, it is -CH2CH2CH3, and R 3 This includes being selected from -CH2CH2CH2NHCO2(t-Bu), -OCH2CH2NHCO2(cyclobutyl), and -CH2CH2CH2NHCO2(cyclobutyl).
[0111] An exemplary embodiment of the immune complex of formula I is R 2 and R 3 However, each is independently selected from -CH2CH2CH3, -OCH2CH3, -OCH2CF3, -CH2CH2CF3, -OCH2CH2OH, and -CH2CH2CH2OH.
[0112] An exemplary embodiment of the immune complex of formula I is R 2 and R 3 However, each of these includes being -CH2CH2CH3.
[0113] An exemplary embodiment of the immune complex of formula I is R 2 However, it is -CH2CH2CH3, and R 3 However, this includes being -OCH2CH3.
[0114] An exemplary embodiment of the immune complex of formula I is X 3 -R 3 but, [ka] This includes being selected from a group consisting of the following:
[0115] An exemplary embodiment of the immune complex of formula I is X 4 However, it is a bond, R 4 This includes being H.
[0116] An exemplary embodiment of the immune complex of formula I is R 1 This includes being bound to L.
[0117] An exemplary embodiment of the immune complex of formula I is R 2 or R 3 This includes being bound to L.
[0118] An exemplary embodiment of the immune complex of formula I is X 3 -R 3 -L is, [ka] A selection is made from the group consisting of the following, and in the formula, the dashed line indicates a connection point to N.
[0119] An exemplary embodiment of the immune complex of formula I is R 4 However, C1-C 12 This includes being alkyl.
[0120] An exemplary embodiment of the immune complex of formula I is R 4 However, -(C1-C 12 Alkyldiyl)-N(R 5 )-*, where the asterisk * indicates the binding site of L.
[0121] Exemplary embodiments of the immune complex of formula I include L being -C(=O)-PEG- or -C(=O)-PEG-C(=O)-.
[0122] An exemplary embodiment of the immune complex of formula I includes a configuration in which L is bound to the cysteinethiol of the antibody.
[0123] An exemplary embodiment of the immune complex of formula I includes, for PEG, m is 1 or 2 and n is an integer between 2 and 10.
[0124] An exemplary embodiment of the immune complex of formula I includes, with respect to PEG, n being 10.
[0125] An exemplary embodiment of the immune complex of formula I is one in which L comprises PEP, PEP is a dipeptide, and formula: [ka] This includes having.
[0126] Exemplary embodiments of the immune complex of formula I include AA1 and AA2 being independently selected from H, -CH3, -CH(CH3)2, -CH2(C6H5), -CH2CH2CH2CH2NH2, -CH2CH2CH2NHC(NH)NH2, -CHCH(CH3)CH3, -CH2SO3H, and -CH2CH2CH2NHC(O)NH2, or AA1 and AA2 forming a five-membered proline amino acid ring.
[0127] Exemplary embodiments of the immune complex of formula I include AA1 being -CH(CH3)2 and AA2 being -CH2CH2CH2NHC(O)NH2.
[0128] Exemplary embodiments of the immune complex of formula I include the selection of AA1 and AA2 independently from GlcNAc aspartate, -CH2SO3H, and -CH2OPO3H.
[0129] An exemplary embodiment of the immune complex of formula I is PEP, which is of formula: [ka] The formula comprises the following, wherein AA1 and AA2 are independently selected from the side chains of naturally occurring amino acids.
[0130] An exemplary embodiment of the immune complex of formula I is one in which L comprises PEP, PEP is a tripeptide, and formula: [ka] This includes having.
[0131] An exemplary embodiment of the immune complex of formula I is one in which L comprises PEP, PEP is a tetrapeptide, and formula: [ka] This includes having.
[0132] An exemplary embodiment of the immune complex of formula I is: AA1 is selected from the group consisting of Abu, Ala, and Val. AA2 is selected from the group consisting of Nle(O-Bzl), Oic, and Pro. AA3 was selected from the group consisting of Ala and Met(O)2. AA4 is selected from the group consisting of Oic, Arg(NO2), Bpa, and Nle(O-Bzl).
[0133] An exemplary embodiment of the immune complex of formula I includes L comprising a PEP, wherein the PEP is selected from the group consisting of Ala-Pro-Val, Asn-Pro-Val, Ala-Ala-Val, Ala-Ala-Pro-Ala, Ala-Ala-Pro-Val, and Ala-Ala-Pro-Nva.
[0134] An exemplary embodiment of the immune complex of formula I is in which L comprises PEP, and PEP has the structure: [ka] This includes being selected from.
[0135] An exemplary embodiment of the immune complex of formula I is shown, where L is structured: [ka] Selected from, in the formula, the wavy line is R 5 This includes demonstrating a connection to [a specific target].
[0136] Equation Ia: [ka] An exemplary embodiment of an immune complex of formula I having the following characteristics.
[0137] An exemplary embodiment of the immune complex of formula Ia is X 4 However, it is a bond, R 4 This includes being H.
[0138] An exemplary embodiment of the immune complex of formula Ia is X 2 and X 3 However, each is a combination, R 2 and R 3 However, independently, C1-C8 alkyl, -O-(C1-C 12 Alkyl), -(C1-C 12 Alkyldiyl)-OR 5 -(C1-C8 alkyldiyl)-N(R 5 )CO2R 5 ,-(C1-C 12 Alkyl)-OC(O)N(R 5 )2, -O-(C1-C 12 Alkyl)-N(R 5 )CO2R 5 , and -O-(C1-C 12 Alkyl)-OC(O)N(R 5 ) This includes being selected from 2.
[0139] Expression Ib ~ If: [ka] [ka] Exemplary embodiments of the immune complex of formula Ia, selected from the following.
[0140] An exemplary embodiment of the immune complex of formula Ia is X 2 and X 3 However, each is a combination, R 2 and R 3 However, independently, C1-C8 alkyl, -O-(C1-C 12 Alkyl), -(C1-C 12 Alkyldiyl)-OR 5 -(C1-C8 alkyldiyl)-N(R 5 )CO2R 5 , and -O-(C1-C 12 Alkyl)-N(R 5 )CO2R 5 This includes being selected from.
[0141] An exemplary embodiment of the immune complex of formula Ia is X 2 and X 3 However, each is a combination, R 2 However, it is a C1-C8 alkyl group, and R 3 However, -O-(C1-C 12 Alkyl), and -O-(C1-C 12 Alkyl)-N(R 5 )CO2R 5 This includes being selected from.
[0142] The present invention includes all reasonable combinations of embodiments of Formula I and substitutions of features.
[0143] In certain embodiments, the immune complex compounds of the present invention include those having immunostimulatory activity. The antibody-drug conjugates of the present invention can selectively deliver an effective dose of an 8-phenyl-2-aminobenzazepine drug to tumor tissue, thereby achieving higher selectivity (i.e., a lower effective dose) while increasing the therapeutic index ("therapeutic concentration range") compared to unconjugated 8-phenyl-2-aminobenzazepine.
[0144] The drug load is represented by p, which is the number of PhBz moieties per antibody in the immune complex of formula I. The drug (PhBz) load can range from 1 to about 8 drug moieties (D) per antibody. The immune complex of formula I comprises a mixture or aggregate of antibodies conjugated with drug moieties ranging from 1 to about 8. In some embodiments, the number of drug moieties that can be conjugated to an antibody is limited by the number of reactive or available amino acid side chain residues, such as lysine and cysteine. In some embodiments, free cysteine residues are introduced into the antibody amino acid sequence by the method described herein. In such embodiments, p may be 1, 2, 3, 4, 5, 6, 7, or 8, and may be in a range therefrom, such as 1 to 8 or 2 to 5. In any such embodiment, p and n are equal (i.e., p = n = 1, 2, 3, 4, 5, 6, 7, or 8, or some range between them). Examples of immunoconjugates of formula I include, but are not limited to, antibodies having one, two, three, or four manipulated cysteine amino acids (Lyon, R. et al. (2012) Methods in Enzym. 502:123-138). In some embodiments, one or more free cysteine residues are already present in the antibody forming an intrachain disulfide bond without manipulation, in which case the existing free cysteine residues may be used to conjugate the antibody to the drug. In some embodiments, the antibody is exposed to reducing conditions prior to antibody conjugation to generate one or more free cysteine residues.
[0145] In some immunocomplexes, p may be limited by the number of binding sites on the antibody. For example, as in certain exemplary embodiments described herein, when the binding is cysteinethiol, the antibody may have only one or a limited number of cysteinethiol groups, or only one or a limited number of sufficiently reactive thiol groups to which the drug may bind. In other embodiments, one or more lysineamino groups in the antibody may be available for conjugation with Hx-linker compounds of formula II and may be reactive. In certain embodiments, a higher drug load, e.g., p > 5, may cause aggregation, insolubility, toxicity, or loss of cell permeability of certain antibody-drug complexes. In certain embodiments, the mean drug load of the immunocomplex is in the range of 1 to about 8, about 2 to about 6, or about 3 to about 5. In certain embodiments, the antibody is subjected to denaturation conditions to reveal reactive nucleophiles such as lysine or cysteine.
[0146] The immune complex load (drug / antibody ratio) can be controlled in different ways, for example, by (i) limiting the molar excess of the Hx-linker intermediate compound relative to the antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or restrictive reductive denaturation conditions for optimized antibody reactivity.
[0147] It should be understood that when two or more nucleophilic groups of an antibody react with a drug, the resulting product is a mixture of immunocomplex compounds having a distribution of one or more drug moieties bound to the antibody. The average number of drugs per antibody can be calculated from the mixture by a bilayer ELISA antibody assay, which is antibody-specific and drug-specific. Individual immune complex molecules can be identified in the mixture by mass spectrometry and separated by HPLC, e.g., hydrophobic interaction chromatography (e.g., McDonagh et al. (2006) Prot.Engr.Design&Selection 19(7):299-307, Hamblet et al. (2004) Clin.Cancer Res.10:7063-7070, Hamblet, KJ, et al. “Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate,” Abstract No. 624, American Association for Cancer Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004, Alley, SC, et al. “Controlling the location of drug attachment in antibody-drug conjugates,” Abstract No. 627, American Association for Cancer See Research, 2004 Annual Meeting, March 27-31, 2004, Proceedings of the AACR, Volume 45, March 2004. In certain embodiments, a homogeneous immunocomplex having a single loading value can be isolated from the conjugation mixture by electrophoresis or chromatography.
[0148] Exemplary embodiments of the immune complex of Formula I are selected from the immune complexes in Tables 3a and 3b. In vitro evaluation of immune complex activity was performed according to the method of Example 203. [Table 4-1] [Table 4-2] [Table 4-3] [Table 5]
[0149] Composition of immune complexes The present invention provides compositions, e.g., pharmaceutically or pharmacologically acceptable compositions or formulations, comprising a plurality of immune complexes described herein and optionally their carriers, e.g., pharmaceutically or pharmacologically acceptable carriers. The immune complexes may be the same or different in the composition; that is, the composition may include immune complexes having the same number of adjuvants linked at the same positions on an antibody construct, and / or immune complexes having the same number of Hx adjuvants linked at different positions on an antibody construct, or immune complexes having different numbers of adjuvants linked at the same positions on an antibody construct, or immune complexes having different numbers of adjuvants linked at different positions on an antibody construct.
[0150] In exemplary embodiments, a composition comprising the immunocomplex compound comprises a mixture of immunocomplex compounds, wherein the average drug (Hx) load per antibody in the mixture of immunocomplex compounds is about 2 to about 5.
[0151] The immunocomplex compositions of the present invention may have an average adjuvant with an antibody-to-antibody ratio (DAR) of about 0.4 to about 10. Those skilled in the art will recognize that the number of 8-Phe-2-aminobenzazepine adjuvants conjugated to the antibody construct may vary among the immunocomplexes in a composition comprising multiple immunocomplexes of the present invention, and therefore the adjuvant-to-antibody construct (e.g., antibody) ratio may be measured as an average, which may be referred to as the drug-to-antibody ratio (DAR). The adjuvant-to-antibody construct (e.g., antibody) ratio can be evaluated by any suitable means, many of which are known in the art.
[0152] The average number of adjuvant sites per antibody (DAR) in the preparation of immune complexes from conjugation reactions can be characterized by conventional methods such as mass spectrometry, ELISA assays, and HPLC. The quantitative distribution of p in the immune complexes within the composition can also be determined. In some cases, the separation, purification, and characterization of homogeneous immune complexes with a specific p value from immune complexes with other drug loads can be achieved by methods such as reverse-phase HPLC or electrophoresis.
[0153] In some embodiments, the composition further comprises one or more pharmaceutically or pharmacologically acceptable excipients. For example, the immune complex of the present invention can be formulated for parenteral administration, such as intravenous administration or administration into the body cavity or lumen of an organ. Alternatively, the immune complex can be injected into a tumor. The injectable composition generally comprises a solution of the immune complex dissolved in a pharmaceutically acceptable carrier. Acceptable vehicles and solvents that can be used include water, as well as isotonic solutions of one or more salts such as sodium chloride, e.g., Ringer's solution. In addition, sterile fixatives can conventionally be used as solvents or suspension media. For this purpose, any sterile fixative, including synthetic monoglycerides or diglycerides, can be used. In addition, fatty acids such as oleic acid can similarly be used in the preparation of injectables. These compositions are preferably sterile and generally free of undesirable substances. These compositions can be sterilized by conventional and well-known sterilization techniques. The composition may contain pharmaceutically acceptable auxiliary substances as necessary to approximate physiological conditions, such as pH adjusters and buffers, toxicity modifiers, and, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
[0154] The composition may contain any preferred concentration of immune complexes. The concentration of immune complexes in the composition may vary considerably and is mainly selected based on fluid volume, viscosity, body weight, etc., depending on the selected specific mode of administration and the patient's needs. In certain embodiments, the concentration of immune complexes in the injectable solution formulation is in the range of about 0.1% (w / w) to about 10% (w / w).
[0155] A method of treating cancer using immune complexes The present invention provides a method for treating cancer. The method comprises administering a therapeutically effective amount of an immune complex described herein (for example, as a composition described herein) to a subject in need, for example, a subject having cancer and in need of cancer treatment. The method comprises administering a therapeutically effective amount of an immune complex (IC) selected from Tables 3a and 3b.
[0156] The immune complexes of the present invention are intended to be used, for example, to treat various hyperproliferative disorders or conditions characterized by the overexpression of tumor antigens. Exemplary hyperproliferative disorders include benign or malignant solid tumors, as well as hematological disorders such as leukemia and lymphoid malignancies.
[0157] In another embodiment, an immune complex for use as a pharmaceutical is provided. In a particular embodiment, the present invention provides an immune complex for use in a method of treating an individual, which includes administering an effective amount of the immune complex to the individual. In such an embodiment, the method further includes administering to the individual an effective amount of, for example, at least one additional therapeutic agent described herein.
[0158] In further embodiments, the present invention provides the use of immune complexes in the manufacture or preparation of pharmaceuticals. In one embodiment, the pharmaceutical is for the treatment of cancer, and the method comprises administering an effective amount of the pharmaceutical to an individual having cancer. In such one embodiment, the method further comprises administering to the individual an effective amount of, for example, at least one additional therapeutic agent described herein.
[0159] Carcinomas are malignant tumors that originate from epithelial tissue. Epithelial cells cover the outer surface of the body, line the lumen, and form the inner lining of glandular tissue. Examples of carcinomas include, but are not limited to, adenocarcinomas (cancers that develop in glandular (secretory) cells, such as breast cancer, pancreatic cancer, lung cancer, prostate cancer, stomach cancer, gastroesophageal junction cancer, and colon cancer), adrenocortical carcinoma, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, carcinoma in situ, ductal carcinoma, breast cancer, basal cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, colon cancer, nasopharyngeal cancer, multiple cystic renal cell carcinoma, oat cell carcinoma, large cell lung cancer, small cell lung cancer, and non-small cell lung cancer. Carcinomas can be found in the prostate, pancreas, colon, brain (usually as secondary metastasis), lungs, breasts, and skin. In some embodiments, a method for treating non-small cell lung cancer involves administering an immune complex containing an antibody construct that can bind to HER2 (e.g., trastuzumab, pertuzumab, their biosimilars, or their biobetters).
[0160] Soft tissue tumors are a highly diverse group of rare tumors originating from connective tissue. Examples of soft tissue tumors include alveolar soft tissue sarcoma, hemangiomatous fibrous histiocytoma, chondromyooxidative fibroma, skeletal chondrosarcoma, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, fibroplastic small round cell tumor, dermatofibrosarcoma protuberans, endometrial stromal tumor, Ewing's sarcoma, fibromatosis (desmoid), infantile fibrosarcoma, gastrointestinal stromal tumor, giant cell tumor of bone, tenosynovial giant cell tumor, inflammatory myofibroblastic tumor, uterine leiomyoma, leiomyosarcoma, lipoblastoma, typical lipoma, spindle cell or pleomorphic lipoma, atypical lipoma, chondrolipoma, well-differentiated liposarcoma, myxoid / round cell liposarcoma, pleomorphic liposarcoma, myxoid malignant fibrous histiocytoma, high-grade malignant fibrous histiocytoma, myxofibrosarcoma, and malignant peripheral nerve This includes, but is not limited to, transshear tumors, mesothelioma, neuroblastoma, osteochondroma, osteosarcoma, primitive neuroectoderm tumors, alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, benign or malignant schwannomas, synovial sarcoma, Evans tumor, nodular fasciitis, desmoid fibromatosis, solitary fibrous tumors, dermatofibrosarcoma protuberans (DFSP), angiosarcoma, epithelioid hemangioendothelioma, tenosynovial giant cell tumor (TGCT), pigmented villonodular synovitis (PVNS), fibrous dysplasia, myxofibrosarcoma, fibrosarcoma, synovial sarcoma, malignant peripheral nerve sheath tumors, neurofibromas, pleomorphic adenomas of soft tissue, as well as neoplasms derived from fibroblasts, myofibroblasts, histiocytes, vascular cells / endothelial cells, and nerve sheath cells.
[0161] Sarcoma is a rare type of cancer that arises in mesenchymal cells, including cartilage, fat, muscle, blood vessels, fibrous tissue, or other connective or supporting tissues, such as bone or soft tissue of the body. Different types of sarcoma are based on where the cancer forms. For example, osteosarcoma forms in bone, liposarcoma forms in fat, and rhabdomyosarcoma forms in muscle. Examples of sarcomas include, but are not limited to, Askin tumors, botryoides sarcomas, chondrosarcomas, Ewing's sarcomas, malignant hemangioendotheliomas, malignant schwannomas, osteosarcomas, and soft tissue sarcomas (e.g., alveolar soft tissue sarcoma, angiosarcoma, cyssarcoma fjordian fibrous sarcoma protoverance (DFSP), desmoid tumors, deplastic small round cell tumors, episarcomas, extraskeletal chondrosarcomas, extraskeletal osteosarcomas, fibrous sarcomas, gastrointestinal stromal tumors (GISTs), vascular carcinomas, angiosarcomas (more commonly referred to as "angiosarcomas"), Kaposi's sarcoma, leiomyosarcomas, liposarcomas, lymphangiosarcomas, malignant peripheral nerve sheath tumors (MPNSTs), neurofibrosarcomas, synovial sarcomas, and undifferentiated pleoplastic sarcomas).
[0162] Deformomas are a type of germ cell tumor that can contain several different types of tissue, including, for example, hair, muscle, and bone (e.g., tissue derived from any and / or all of the three germ layers: endoderm, mesoderm, and ectoderm). Deformomas most frequently occur in the ovaries of women, the testicles of men, and the coccyx of children.
[0163] Melanoma is a type of cancer that develops in melanocytes (cells that produce the pigment melanin). Melanoma can develop in moles (cutaneous melanoma), but it can also develop in other pigmented tissues such as the eyes or intestines.
[0164] Merkel cell carcinoma is a rare type of skin cancer that typically appears as flesh-colored or bluish-red nodules on the face, head, or neck. Merkel cell carcinoma is also known as neuroendocrine carcinoma of the skin. In some embodiments, a method for treating Merkel cell carcinoma involves administering an immune complex containing an antibody construct that can bind to HER2 (e.g., trastuzumab, pertuzumab, their biosimilars, or their biobetter). In some embodiments, the Merkel cell carcinoma has metastasized by the time the administration occurs.
[0165] Leukemia is a type of cancer that originates in blood-forming tissues such as bone marrow, where a large number of abnormal blood cells are produced and enter the bloodstream. For example, leukemia can originate from bone marrow-derived cells that normally mature in the bloodstream. Leukemias are named according to the speed of onset and progression of the disease (e.g., acute vs. chronic) and the type of white blood cells affected (e.g., bone marrow vs. lymphocyte). Myeloid leukemia is also called myeloid or myeloblastic leukemia. Lymphoblastic leukemia is also called lymphoblastic or lymphocytic leukemia. Lymphoblastic leukemia cells can accumulate in lymph nodes, which can cause swelling. Examples of leukemia include, but are not limited to, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL).
[0166] Lymphoma is a type of cancer that develops in the cells of the immune system. For example, lymphoma can originate from bone marrow-derived cells that normally mature in the lymphatic system. There are two basic categories of lymphoma. One category of lymphoma is Hodgkin lymphoma (HL), which is characterized by the presence of a type of cell called Reed-Sternberg cells. Currently, six types of HL are recognized. Examples of Hodgkin lymphoma include tuberous sclerosis classical Hodgkin lymphoma (CHL), mixed-cell CHL, lymphopenic CHL, lymphocyte-rich CHL, and nodular lymphocytosis-dominant HL.
[0167] Another category of lymphoma is non-Hodgkin lymphoma (NHL), which includes a large and diverse group of cancers of immune system cells. NHLs are further divided into those with a slow course and those with a rapid course. Currently, 61 types of NHL are recognized. Examples of non-Hodgkin lymphomas include, but are not limited to, AIDS-related lymphoma, anaplastic large cell lymphoma, angioimmunoblastic lymphoma, blastic NK cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma (small unsevered cell lymphoma), chronic lymphocytic leukemia / small lymphocytic lymphoma, cutaneous T-cell lymphoma, diffuse large B-cell lymphoma, enteropathy-type T-cell lymphoma, follicular lymphoma, hepatosplenic gamma delta T-cell lymphoma, T-cell leukemia, lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, nasal T-cell lymphoma, pediatric lymphoma, peripheral T-cell lymphoma, primary central nervous system lymphoma, transformed lymphoma, treatment-associated T-cell lymphoma, and Valdenström macroglobulinemia.
[0168] Brain tumors include all cancers of brain tissue. Examples of brain tumors include, but are not limited to, gliomas (e.g., glioblastoma, astrocytoma, oligodendroglioma, ependymoma, etc.), meningiomas, pituitary adenomas, and vestibular schwannomas and primitive neuroectodermal tumors (medulloblastomas).
[0169] The immune complex of the present invention may be used in therapy either alone or in combination with other agents. For example, the immune complex may be administered with at least one additional therapeutic agent, such as a chemotherapeutic agent. Such combination therapy includes combined administration (where two or more therapeutic agents are contained in the same or separate formulations) and separate administration, in which case the administration of the immune complex may occur before, simultaneously with, and / or after the administration of the additional therapeutic agent and / or adjuvant. The immune complex may also be used in combination with radiotherapy.
[0170] The immune complex of the invention (and any additional therapeutic agents) may be administered by any preferred means, including parenteral, intrapulmonary, intranasal, and, if desired for topical treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Dosage may be carried out by injection, such as intravenous or subcutaneous injection, depending in part whether the administration is short-term or chronic. Various dosing schedules, including but not limited to single or multiple doses at various time points, bolus administration, and pulse infusion, are contemplated herein.
[0171] The immune complex is administered to the target in need at any therapeutically effective dose using any appropriate drug regimen, such as rabetuzumab, its biosimilars, and its biobetters. For example, this method may include administering the immune complex to provide a target with a dose of approximately 100 ng / kg to approximately 50 mg / kg. The immune complex dose may be in the range of approximately 5 mg / kg to approximately 50 mg / kg, approximately 10 μg / kg to approximately 5 mg / kg, or approximately 100 μg / kg to approximately 1 mg / kg. The immune complex dose may be approximately 100, 200, 300, 400, or 500 μg / kg. The immune complex dose may be approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg / kg. The immune complex dose may also be outside these ranges, depending on the specific complex, as well as the type and severity of the cancer being treated. The frequency of administration may range from a single dose to multiple doses per week or more. In some embodiments, the immune complex is administered about once a month to about five times a week. In some embodiments, the immune complex is administered once a week.
[0172] In another embodiment, the present invention provides a method for preventing cancer. The method comprises administering a therapeutically effective amount of an immune complex (e.g., as the above composition) to a subject. In a particular embodiment, the subject is susceptible to a particular cancer to be prevented.
[0173] Some embodiments of the present invention provide methods for treating the above-described cancer, where the cancer is breast cancer. Breast cancer can originate from different areas of the breast, and a number of different types of breast cancer have been characterized. For example, the immune complexes of the present invention may be used to treat ductal carcinoma in situ, invasive ductal carcinoma (e.g., tubular carcinoma, medullary carcinoma, mucinous carcinoma, papillary carcinoma, or cribriform carcinoma), lobular carcinoma in situ, invasive lobular carcinoma, inflammatory breast cancer, and other forms of breast cancer such as triple-negative (test negative for estrogen receptor, progesterone receptor, and excess HER2 protein) breast cancer. In some embodiments, the method for treating breast cancer involves administering an immune complex containing an antibody construct that can bind to HER2, or to a tumor that overexpresses HER2 (e.g., trastuzumab, pertuzumab, their biosimilars, or biobetter).
[0174] In some embodiments, cancer is sensitive to pro-inflammatory responses induced by TLR7 and / or TLR8.
[0175] In some embodiments, a therapeutically effective dose of immune complexes is administered to patients who require treatment for cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, esophageal cancer, bladder cancer, urinary tract cancer, urothelial cancer, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, or breast cancer. Merkel cell carcinoma may be metastatic Merkel cell carcinoma. Breast cancer may be triple-negative breast cancer. Esophageal cancer may be gastroesophageal junction adenocarcinoma. [Examples]
[0176] Example L-42 Synthesis of 2,3,5,6-tetrafluorophenyl 1-(1-((3-(2-amino-4-(ethoxy(propyl)carbamoyl)-3H-benzo[b]azepine-8-yl)phenyl)sulfonyl)azetidine-3-yl)-3-oxo-6,9,12,15,18,21,24,27,30,33-decaoxa-2-azahexatriacontane-36-oate, PhBzL-42 [ka] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[1-[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepine-8-yl]phenyl]sulfonylazetidine-3-yl]methylamino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate, PhBzL-42b A solution of 2-amino-8-[3-[3-(aminomethyl)azetidine-1-yl]sulfonylphenyl]-N-ethoxy-N-propyl-3H-1-benzazepine-4-carboxamide and PhBzL-42a (270 mg, 431 umol, 1 equivalent, TFA) in DMF (2 mL) contains Et3N (131 mg, 1.29 mmol, 180 uL, 3 equivalents) and (2,3,5,6-Te Trafluorophenyl)3-[2-[2-[2-[2-[2-[2-[2-[2-[2-(3-tert-butoxy-3-oxo-propoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate, TFP-PEG10-CO2H (329 mg, 431 umol, 1 equivalent) was added, and the mixture was stirred at 0°C for 1 hour. The mixture was filtered and purified by preparative HPLC (column: Phenomenex Luna 80*30 mm*3 um, mobile phase: [water (0.1% TFA)-ACN], B%: 35%~57%, 8 min) to obtain PhBzL-42b (270 mg, 243 umol, yield 56.45%) as a colorless oil.
[0177] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[1-[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepine-8-yl]phenyl]sulfonylazetidine-3-yl]methylamino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-42c To a solution of PhBzL-42b (270 mg, 243 µl, 1 equivalent) in CH3CN (2 mL) and H2O (2 mL), TFA (222 mg, 1.95 mmol, 144 µL, 8 equivalents) was added and the mixture was stirred at 80°C for 1 hour. The mixture was concentrated, the residue was diluted with water (10 mL), and the pH of the aqueous phase was adjusted to approximately 5 by gradually adding an aqueous solution of NaHCO3. The mixture was extracted with DCM:i-PrOH = 3:1 (10 mL x 3), the organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 75*30mm*3um, mobile phase: [water (0.2% FA)-ACN], B%: 20%~50%, 8 min) to obtain PhBzL-42c (50 mg, 47.52 umol, yield 19.51%) as a colorless oil. 1 H NMR (400 MHz, MeOD) δ8.16-8.09 (m, 2H), 7.94-7.79 (m, 2H), 7.75 (s, 1H), 7.73-7.62 (m, 2H), 7.41 (s, 1H), 3.97 (q, J = 7.0 Hz, 2H), 3.86 (t, J = 8.2 Hz, 2H), 3.79-3.69 (m, 4H), 3.66-3.49 (m, 40H), 3.32 (s, 2H), 3.18 (d, J = 6.4 Hz, 2H), 2.71-2.61 (m, 1H), 2.48 (t, J = 6.5 Hz, 2H), 2.30 (t, J = 6.0 Hz, 2H), 1.78 (sxt, J = 7.2 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.2 Hz, 3H).
[0178] Preparation of PhBzL-42 To a solution of PhBzL-42c (50 mg, 72 umol, 1 equivalent, TFA) in DCM (2 mL) and DMA (0.1 mL), 2,3,5,6-tetrafluorophenol (95 mg, 503 umol, 8 equivalents), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and EDCI (140 mg, 700 umol, 10 equivalents) were added, and the mixture was stirred at 25°C for 0.5 hours. The reaction mixture was diluted with water and purified by HPLC to obtain PhBzL-42 (0.046 g, 0.038 mmol, 53%). LC / MS[M+H] 1200.50 (calculated value), LC / MS[M+H] 1200.80 (observed value).
[0179] Example L-51 Synthesis of 4-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoyloxy]-2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-51 [ka] Preparation of methyl 4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepine-8-yl)benzoate, PhBz-4 A mixture of 2-amino-8-bromo-N-ethoxy-N-propyl-3H-1-benzazepine-4-carboxamide, PhBz-4a (0.2 g, 546 umol, 1 equivalent), (4-methoxycarbonylphenyl)boronic acid (98.3 mg, 546 umol, 1 equivalent), K2CO3 (151 mg, 1.09 mmol, 2 equivalents), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride, and Pd(dppf)Cl2 (40.0 mg, 54.6 umol, 0.1 equivalent) in dioxane (50 mL) and H2O (5 mL) was degassed, purged three times with N2, and then stirred at 90°C for 2 hours under an N2 atmosphere. The mixture was diluted with H2O (10 mL) and extracted with  (30 mL x 3). The mixed organic layer was washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150*25*10um, mobile phase: [water (0.1% TFA)-ACN], B%: 25%~45%, 8 min) to obtain PhBz-4 (0.25 g, crude product) as a white solid. 1 H NMR (MeOD, 400 MHz) δ 8.15 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 Hz, 2H), 7.79-7.75 (m, 1H), 7.71-7.67 (m, 2H), 7.45 (s, 1H), 4.01-3.96 (m, 2H), 3.95 (s, 3H), 3.76 (t, J = 7.2 Hz, 2H), 3.43 (s, 2H), 1.80-1.75 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.6Hz, 3H). HPLC: 98.776% (220nm), 99.813% (254nm). LC / MS[M+H]: 422.2 (calculated value), LC / MS[M+H]: 422.1 (observed value).
[0180] Preparation of 4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoic acid, PhBzL-51a To a solution of PhBz-4 (0.2 g, 474 umol, 1 equivalent) in MeOH (20 mL) and H2O (10 mL), LiOH.H2O (119 mg, 2.85 mmol, 6 equivalents) was added and the mixture was stirred at 20°C for 12 hours. The pH of the mixture was adjusted to approximately 7 with HCl (4 M), and then concentrated as a brown solid under reducing conditions of PhBzL-51a (0.16 g, 393 umol, yield 82.75%). 1 H NMR (DMSO-d6, 400 MHz) δ 8.06 (br d, J = 8.4 Hz, 2H), 7.83 (br d, J = 8.4 Hz, 2H), 7.78-7.63 (m, 3H), 7.32-7.24 (m, 1H), 4.02-3.77 (m, 2H), 3.63 (t, J = 7.2 Hz, 2H), 3.37 (s, 2H), 1.74-1.58 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.6 Hz, 3H).
[0181] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate, PhBz-51b To a solution of PhBz-11a (0.11 g, 270 umol, 1 equivalent) and tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanate (190 mg, 324 umol, 1.2 equivalents), azabenzotriazole tetramethyluronium hexafluorophosphate, HATU (113 mg, 297 umol, 1.1 equivalents) and DIEA (174 mg, 1.35 mmol, 235 uL, 5 equivalents) were added, and the mixture was then stirred at 20°C for 12 hours. The reaction mixture was filtered and purified by preparative HPLC (column: Phenomenex Luna C18 100*30mm*5um, mobile phase: [water (0.1% TFA)-ACN], B%: 30%~40%, 10 min) to obtain PhBz-51b (0.09g, 92.29umol, yield 34.19%) as a white solid.
[0182] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-51c To a solution of PhBzL-51b (0.09 g, 92.3 umol, 1 equivalent) in MeCN (1 mL) and H2O (2 mL), HCl (12 M, 153 uL, 20 equivalents) was added, and the mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain PhBzL-51c (0.06 g, 65.3 umol, yield 70.74%) as a white solid.
[0183] Preparation of PhBzL-51 To a solution of PhBzL-51c (0.06 g, 65.3 umol, 1 equivalent) and (2,3,5,6-tetrafluoro-4-hydroxy-phenyl)sulfonyloxysodium (87.5 mg, 326 umol, 5 equivalents) in DCM (2 mL) and DMA (0.2 mL), EDCI (62.6 mg, 326 umol, 5 equivalents) was added, and the mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the DCM. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150 × 25 × 10 μm, mobile phase: [water (0.1% TFA)-ACN], B%: 15%~40%, 10 min) to obtain PhBzL-51 (0.005 g, 4.36 umol, yield 6.68%) as a yellow oil. 1 H NMR (MeOH, 400 MHz) δ 7.98 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 8.4 Hz, 1H), 7.73 (s, 1H), 7.69-7.65 (m, 1H), 7.45 (s, 1H), 3.98 (q, J = 7.2 Hz, 2H), 3.85 (t, J = 5.6 Hz, 2H), 3.76 (t, J = 7.2 Hz, 2H), 3.71-3.53 (m, 38H), 3.44 (s, 2H), 2.96 (t, J = 5.6 Hz, 2H), 1.88-1.71 (m, 2H), 1.21 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.6 Hz, 3H). HPLC: 95.471% (220nm), 94.988% (254nm). LC / MS[M+H]1147.4 (calculated value), LC / MS[M+H]1147.4 (observed value).
[0184] Example L-54 synthesis of tert-butyl(3-(2-amino-8-(3-((3-(15-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-3,13-dioxo-6,9-dioxa-2,12-diazapentadecyl)azetidine-1-yl)sulfonyl)phenyl)-N-propyl-3H-benzo[b]azepine-4-carboxamide)propyl)carbamate, PhBzL-54 [ka] To a solution of tert-butyl(3-(2-amino-8-(3-((3-(aminomethyl)azetidine-1-yl)sulfonyl)phenyl)-N-propyl-3H-benzo[b]azepine-4-carboxamide)propyl)carbamate, PhBzL-54a (50 mg, 0.08 mmol, 1 equivalent), and 2,5-dioxopyrrolidine-1-yl3-(2-(2-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)propanamide)ethoxy)ethoxy)propanate (34 mg, 0.08 mmol, 1 equivalent), 2,4,6-collidine (21 μl, 0.16 mmol, 2 equivalents) was added. The reaction mixture was stirred at room temperature for 2 hours, then diluted with water, purified by preparative HPLC, and lyophilized to obtain PhBzL-54 (39 mg, 0.041 mmol, 52%) as a white solid. LC / MS[M+H]935.4 (calculated value), LC / MS[M+H]935.8 (observed value).
[0185] Example L-55 synthesis of tert-butyl(3-(2-amino-8-(3-((3-(39-(2,5-dioxo-2,5-dihydro-1H-pyrrole-1-yl)-3,37-dioxo-6,9,12,15,18,21,24,27,30,33-decaxa-2,36-diazanonatriacontyl)azetidine-1-yl)sulfonyl)phenyl)-N-propyl-3H-benzo[b]azepine-4-carboxamide)propyl)carbamate, PhBzL-55 [ka] DMF (1 ml) contains tert-butyl(3-(2-amino-8-(3-((3-(aminomethyl)azetidine-1-yl)sulfonyl)phenyl)-N-propyl-3H-benzo[b]azepine-4-carboxamide)propyl) carbamate, PhBzL-54a (50 mg, 0.08 mmol, 1 equivalent), and 1-(2,5-dioxo-2,5-dihydro-1H To a solution of -pyrrole-1-yl)-3-oxo-7,10,13,16,19,22,25,28,31,34-decaoxa-4-azaheptatriacontan-37-acid (52.8 mg, 0.078 mmol, 0.97 equivalents), DIPEA (28 μl, 0.16 mmol, 2 equivalents) was added, followed by HATU (36.5 mg, 0.096 mmol, 1.2 equivalents). The reaction mixture was stirred at room temperature for 2 hours, then concentrated and purified by preparative HPLC to obtain PhBzL-55 (28.9 mg, 0.022 mmol, 28%). LC / MS[M+H] 1287.6 (calculated value), LC / MS[M+H] 1288.1 (observed value).
[0186] Example L-56 Synthesis of 4-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[1-[3-[2-amino-4-[2-(cyclobutoxycarbonylamino)ethoxy-propyl-carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylazetidine-3-yl]methylamino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoyloxy]-2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-56 [ka] Preparation of cyclobutyl N-[2-[[2-amino-8-[3-[3-[(tert-butoxycarbonylamino)methyl]azetidine-1-yl]sulfonylphenyl]-3H-1-benzazepine-4-carbonyl]-propyl-amino]oxyethyl]carbamate, PhBz-12b To a mixture of cyclobutyl N-[2-(propylaminooxy)ethyl]carbamate (288 mg, 1.14 mmol, 1.5 equivalents, HCl) and 2-amino-8-[3-[3-[(tert-butoxycarbonylamino)methyl]azetidine-1-yl]sulfonylphenyl]-3H-1-benzazepine-4-carboxylic acid, PhBz-12a (400 mg, 760 umol, 1.0 equivalent), EDCI (582 mg, 3.04 mmol, 4.0 equivalents) was added all at once under N2 conditions at 25°C, and then stirred at 25°C for 2 hours. DCM (10 mL) was removed under vacuum, water (15 mL) was added, the aqueous phase was extracted with ethyl acetate (10 mL x 4), the mixed organic phase was washed with brine (20 mL x 2), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, petroleum ether / ethyl acetate = 10 / 1, 0 / 1) to obtain PhBz-12b (340 mg, 469 umol, yield 61.7%) as a brown solid. 1 H NMR (400 MHz, MeOD) δ8.12-8.05 (m, 2H), 7.90-7.83 (m, 1H), 7.82-7.76 (m, 1H), 7.58-7.50 (m, 2H), 7.49-7.42 (m, 1H), 7.33 (s, 1H), 4.76-4.67 (m, 1H), 3.96 (t, J = 5.2 Hz, 2H), 3.85 (t, J = 8.0 Hz, 2H), 3.75 (t, J = 7.2 Hz, 2H), 3.61-3.53 (m, 2H), 3.05 (d, J = 6.8 Hz, 2H), 2.63-2.54 (m, 1H), 2.19 (d, J = 8.9 Hz, 2H), 1.95-1.85 (m, 2H), 1.83-1.75 (m, 2H), 1.66 (d, J = 10.0 Hz, 1H), 1.60-1.48 (m, 1H), 1.39 (s, 9H), 1.00 (t, J = 7.2 Hz, 3H).
[0187] Preparation of cyclobutyl N-[2-[[2-amino-8-[3-[3-(aminomethyl)azetidine-1-yl]sulfonylphenyl]-3H-1-benzazepine-4-carbonyl]-propyl-amino]oxyethyl]carbamate, PhBz-12 To a solution of PhBz-12b (290 mg, 400 umol, 1.0 equivalent) in MeCN (5 mL) and H2O (5 mL), TFA (456 mg, 4.00 mmol, 296 uL, 10 equivalents) was added all at once under N2 conditions at 25°C, and the mixture was stirred at 80°C for 1 hour. The MeCN (5 mL) was removed under vacuum, and the aqueous phase was extracted with methyl tert-butyl ether (5 mL x 3) to remove excess TFA. The aqueous phase was then freeze-dried to obtain PhBz-12 (280 mg, 379 umol, yield 94.7%, TFA) as a yellow solid.
[0188] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[[1-[3-[2-amino-4-[2-(cyclobutoxycarbonylamino)ethoxy-propyl-carbamoyl]-3H-1-benzazepine-8-yl]phenyl]sulfonylazetidine-3-yl]methylamino]-3-oxo-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-56a A mixture of PhBz-12 (100 mg, 160 umol, 1.0 equivalent) and Et3N (48.6 mg, 480 umol, 66.8 uL, 3.0 equivalents) in THF (2 mL) contains 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-oxo-3-(2,3,5,6-tetrafluorophenoxy)propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, TFP-PEG 10-CO2H (113 mg, 160 umol, 1.0 equivalent) was added all at once at 0°C under N2, the mixture was stirred at 0°C for 30 minutes, then heated to 25°C and stirred for a further 0.5 hours. The reaction mixture was quenched with TFA until the pH reached 6 at 0°C, then water (5 mL) was added, the aqueous phase was extracted with ethyl acetate (3 mL), the ethyl acetate phase was discarded, and the aqueous phase was further extracted with DCM:i-PrOH / 3:1 (5 mL x 3). The mixed organic phase was concentrated under vacuum to obtain PhBzL-56a (160 mg, 137 umol, yield 85.7%) as a yellow oil.
[0189] Preparation of PhBzL-56 To a mixture of PhBzL-56a (80.0 mg, 68.6 umol, 1.0 equivalent) and (2,3,5,6-tetrafluoro-4-hydroxyphenyl)sulfonyloxysodium (92.0 mg, 343 umol, 5.0 equivalents) in DCM (1 mL) and DMA (0.2 mL), EDCI (65.8 mg, 343 umol, 5.0 equivalents) was added all at once under N2 conditions at 25°C, and the mixture was stirred at 25°C for 1 hour. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 30%~60%, 8 min) to obtain PhBzL-56 (45.0 mg, 25.2 umol, yield 36.6%, purity 78.0%) as a yellow oil. The crude product was further purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 25%~50%, 8 min) to obtain PhBzL-56 (13.8 mg, 9.37 umol, yield 29.0%, purity 94.6%) as a yellow oil. 1H NMR (400 MHz, MeOD) δ8.16-8.08 (m, 2H), 7.93 (d, J = 7.6 Hz, 1H), 7.89-7.80 (m, 3H), 7.79 (s, 1H), 7.53 (s, 1H), 4.69-4.66 (m, 1H), 3.99 (t, J = 4.8 Hz, 2H), 3.93-3.84 (m, 4H), 3.81-3.74 (m, 2H), 3.72-3.50 (m, 40H), 3.46 (s, 2H), 3.18 (d, J = 6.4 Hz, 2H), 2.99 (t, J = 5.6 Hz, 2H), 2.74-2.64 (m, 1H), 2.30 (t, J = 6.0 Hz, 2H), 2.24-2.15 (m, 2H), 1.94-1.84 (m, 2H), 1.79 (br dd, J = 7.2, 14.4 Hz, 2H), 1.71-1.62 (m, 1H), 1.59-1.49 (m, 1H), 1.02 (t, J = 7.2 Hz, 3H). LC / MS[M+H]1393.5 (calculated value), LC / MS[M+H]1393.2 (observed value).
[0190] Example L-58 Synthesis of 4-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2R)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoyloxy]-2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-58 [ka] Preparation of methyl(2R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidine-2-carboxylate, PhBz-16b To a solution of methyl(2R)-pyrrolidine-2-carboxylate (334 mg, 2.02 mmol, 1 equivalent, HCl), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, and PhBz-16a (0.5 g, 2.02 mmol, 1 equivalent) in DMF (5 mL), HATU (766 mg, 2.02 mmol, 1 equivalent) and DIEA (781 mg, 6.05 mmol, 1.05 mL, 3 equivalents) were added, and the mixture was stirred at 20°C for 2 hours. The reaction mixture was quenched with added H2O (10 mL) and extracted with siRNA (10 mL x 3). The mixed organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain PhBz-16b (1.5 g, crude) as a yellow oil.
[0191] Preparation of (2R)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carboxylate, PhBz-16 A mixture of PhBz-16b (0.7 g, 1.95 mmol, 1 equivalent), 2-amino-8-bromo-N-ethoxy-N-propyl-3H-1-benzazepine-4-carboxamide (714 mg, 1.95 mmol, 1 equivalent), K2CO3 (539 mg, 3.90 mmol, 2 equivalents), and Pd(dppf)Cl2 (143 mg, 195 µm, 0.1 equivalent) in dioxane (20 mL) and H2O (2 mL) was degassed, purged three times with N2, and then stirred at 90°C for 2 hours under an N2 atmosphere. The reaction mixture was extracted with siRNA (30 mL x 3). The mixed organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 25%~50%, 8 min) to obtain PhBz-16 (0.5g, 964umol, yield 49.48%) as a white solid. 1H NMR (MeOH, 400 MHz) δ 7.86-7.64 (m, 7H), 7.45 (s, 1H), 4.64 (dd, J = 5.2, 8.4 Hz, 1H), 3.98 (q, J = 7.2 Hz, 2H), 3.83-3.73 (m, 5H), 3.72-3.58 (m, 2H), 3.48 (s, 2H), 2.50-2.33 (m, 1H), 2.14-1.91 (m, 3H), 1.78 (t, J = 7.2 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H), 1.01 (t, J = 7.6 Hz, 3H). LC / MS[M+H] 519.3 (calculated value), LC / MS[M+H] 519.2 (observed value).
[0192] Preparation of (R)-1-(4-(2-amino-4-(ethoxy(propyl)carbamoyl)-3H-benzo[b]azepine-8-yl)benzoyl)pyrrolidine-2-carboxylic acid, PhBzL-56a To a solution of PhBz-16 (0.5 g, 964 umol, 1 equivalent) in MeOH (20 mL), LiOH.H2O (121 mg, 2.89 mmol, 3 equivalents) in H2O (2 mL) was added, and the mixture was stirred at 20°C for 2 hours. The pH of the reaction mixture was adjusted to approximately 5 with HCl (4 M), and then filtered to obtain PhBzL-56a (0.2 g, 396 umol, yield 41.11%) as a brown solid.
[0193] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2R)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanete, PhBzL-58b To a solution of PhBzL-58a (0.2 g, 369 umol, 1 equivalent) and tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate (279 mg, 476 umol, 1.2 equivalents), DIEA (256 mg, 1.98 mmol, 345 uL, 5 equivalents) and HATU (166 mg, 436 mmol, 1.1 equivalents) were added and the mixture was stirred at 20°C for 2 hours. The reaction mixture was filtered and purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 20%~50%, 8 min) to obtain PhBzL-58b (0.15g, 139.89umol, yield 35.29%) as a yellow oil.
[0194] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2R)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-58c To a solution of PhBzL-58b (0.15 g, 140 umol, 1 equivalent) in MeCN (2 mL) and H2O (1 mL), HCl (12 M, 233 uL, 20 equivalents) was added, and the mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain PhBzL-56c (0.11 g, 108 umol, yield 77.38%) as a white oil.
[0195] Preparation of PhBzL-58 To a solution of PhBzL-58c (0.11 g, 108 umol, 1 equivalent) and (2,3,5,6-tetrafluoro-4-hydroxyphenyl)sulfonyloxysodium (116 mg, 433 umol, 4 equivalents) in DCM (2 mL) and DMA (0.1 mL), EDCI (83.0 mg, 433 umol, 4 equivalents) was added, and the mixture was stirred at 20°C for 1 hour. The reaction mixture was filtered and concentrated under vacuum to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150 × 25 × 10 μm, mobile phase: [water (0.1% TFA)-ACN], B%: 15%~40%, 8 min) to obtain PhBzL-58 (53.8 mg, 43.24 umol, yield 39.94%) as yellow oil. 1 H NMR (MeOH, 400 MHz) δ7.85-7.64 (m, 6H), 7.56 (br d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 4.62-4.39 (m, 1H), 3.98 (q, J = 7.2 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 3.82-3.70 (m, 4H), 3.69-3.49 (m, 36H), 3.49-3.35 (m, 5H), 3.24-3.05 (m, 1H), 2.96 (t, J = 6.0 Hz, 2H), 2.49-2.26 (m, 1H), 2.12-1.87 (m, 3H), 1.84-1.71 (m, 2H), 1.28-1.15 (m, 3H), 1.01 (t, J = 7.6 Hz, 3H). LC / MS[M+H]1244.5 (calculated value), LC / MS[M+H]1244.4 (observed value).
[0196] Example L-59 Synthesis of 4-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoyloxy]-2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-59 [ka] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[(3-bromophenyl)sulfonylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanete, PhBzL-59b To a solution of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate (500 mg, 854 umol, 1 equivalent) and 3-bromobensulfonyl chloride, PhBzL-59a (218 mg, 854 umol, 123 uL, 1 equivalent), Et3N (173 mg, 1.71 mmol, 23 uL, 2 equivalents) was added and the mixture was stirred at 25°C for 0.5 hours. The reaction mixture was diluted with water (10 mL) and extracted with DCM (20 mL x 3). The mixed organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. This residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 50 / 1 to ethyl acetate:MeOH = 10:1) to obtain PhBzL-59b (400 mg, 497 umol, yield 58.2%) as a yellow oil.
[0197] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate, PhBzL-59c To a solution of PhBzL-59b (200 mg, 249 umol, 1 equivalent) and 2-amino-N-ethoxy-N-propyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-benzo[b]azepine-4-carboxamide (103 mg, 249 umol, 1 equivalent) in dioxane (2 mL), a solution of K2CO3 (68.7 mg, 497 umol, 2 equivalents) and Pd(dppf)Cl2 (9.09 mg, 12.4 umol, 0.05 equivalents) in water (0.5 mL) was added under N2 conditions, and the mixture was stirred at 90°C for 5 hours. The mixture was filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (TFA conditions, column: Phenomenex luna C18 100×40mm×5um, mobile phase: [water (0.1% TFA)-ACN], B%: 20%~53%, 8 min) to obtain PhBzL-59c (50 mg, 49.5 umol, yield 19.90%) as a yellow oil. 1 H NMR (400MHz, MeOD) δ 8.22 (s, 1H), 7.98 (dd, J = 8.0, 16.6 Hz, 2H), 7.83-7.72 (m, 4H), 7.49 (s, 1H), 4.01 (q, J = 7.2 Hz, 2H), 3.78 (t, J = 7.2 Hz, 2H), 3.69 (t, J = 6.4 Hz, 2H), 3.66-3.52 (m, 34H), 3.51-3.46 (m, 6H), 3.15 (t, J = 5.2 Hz, 2H), 2.47 (t, J = 6.4 Hz, 2H), 1.84-1.77 (m, 2H), 1.72-1.65 (m, 1H), 1.46 (s, 9H), 1.24 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.6 Hz, 3H).
[0198] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-59d To a solution of PhBzL-59c (50 mg, 49.5 umol, 1 equivalent) in MeCN (0.2 mL) and water (2 mL), HCl (12 M, 61.8 uL, 15 equivalents) was added, and the mixture was stirred at 80°C for 2 hours. The mixture was concentrated under reduced pressure to obtain PhBzL-59d (45 mg, 45.4 umol, yield 91.8%, HCl) as a yellow oil.
[0199] Preparation of PhBzL-59 To a solution of PhBzL-59d (45 mg, 45.4 umol, 1 equivalent, HCl) and sodium 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonate (48.7 mg, 182 umol, 4 equivalents) in DCM (0.3 mL) and DMA (0.3 mL), EDCI (34.8 mg, 182 umol, 4 equivalents) was added and the mixture was stirred at 25°C for 0.5 hours. The mixture was filtered, concentrated under reduced pressure, and purified by preparative HPLC (TFA conditions, column: Phenomenex Synergi C18 150 × 25 × 10 μm, mobile phase: [water (0.1% TFA)-ACN], B%: 20%~50%, 8 min) to obtain PhBzL-59 (22 mg, 18.6 umol, yield 40.97%) as a yellow solid. 1 H NMR (400MHz, MeOD) δ 8.22 (s, 1H), 7.97 (dd, J = 8.4, 16.8 Hz, 2H), 7.83-7.68 (m, 4H), 7.48 (s, 1H), 4.00 (q, J = 6.8 Hz, 2H), 3.87 (t, J = 6.0 Hz, 2H), 3.78 (t, J = 7.2 Hz, 2H), 3.66-3.46 (m, 42H), 3.15 (t, J = 5.2 Hz, 2H), 2.98 (t, J = 6.0 Hz, 2H), 1.85-1.74 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.6 Hz, 3H). LC / MS[M+H]1183.4 (calculated value), LC / MS[M+H]1183.6 (observed value).
[0200] Example L-61 Synthesis of 4-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2S)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoyloxy]-2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-61 [ka] Preparation of methyl(2S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidine-2-carboxylate, PhBz-11b To a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (500 mg, 2.02 mmol, 1.0 equivalent) and (S)-methylpyrrolidine-2-carboxylate, PhBz-11a (367 mg, 2.22 mmol, 1.1 equivalents, HCl) in DMF (3 mL), DIEA (1.04 g, 8.06 mmol, 1.40 mL, 4.0 equivalents) and HATU (766 mg, 2.02 mmol, 1.0 equivalent) were added all at once under N2 conditions at 25°C, and the mixture was stirred at 25°C for 1.5 hours. Water (10 mL) was added, the aqueous phase was extracted with ethyl acetate (10 mL x 3), the mixed organic phase was washed with brine (10 mL x 2), dried with anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain PhBz-11b (700 mg, crude product) as a colorless oil.
[0201] Preparation of methyl 1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carboxylate, PhBz-11 The intermediates PhBz-11b (650 mg, 1.81 mmol, 1.0 equivalent), 2-amino-8-bromo-N-ethoxy-N-propyl-3H-1-benzazepine-4-carboxamide (663 mg, 1.81 mmol, 1.0 equivalent), Pd(dppf)Cl2 (132 mg, 181 mmol, 0.1 equivalent), and K2CO3 (500 mg, 3.62 mmol, 2.0 equivalents) in dioxane (8 mL) and H2O (2 mL) were degassed and then heated at 95°C for 2 hours under N2. Dioxane was removed under vacuum, water (10 mL) was added, the aqueous phase was extracted with ethyl acetate (10 mL x 3), the mixed organic phase was washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (column height: 250 mm, diameter: 100 mm, 100-200 mesh silica gel, petroleum ether / ethyl acetate = 10 / 1, 0 / 1) to obtain PhBz-11 (700 mg, 1.35 mmol, yield 74.6%) as a yellow solid.
[0202] Preparation of 1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepine-8-yl]benzoyl]pyrrolidine-2-carboxylic acid, PhBzL-61a To a solution of PhBz-11 (300 mg, 578 ml, 1.0 equivalent) in MeOH (5 mL) and H2O (5 mL), LiOH·H2O (97.1 mg, 2.31 mmol, 4.0 equivalents) was added all at once under N2 conditions at 25°C, and the mixture was stirred at 25°C for 10 hours. The reaction mixture was quenched with HCl (4 M) to pH=7, MeOH (5 mL) was removed under vacuum, and the aqueous phase was extracted with DCM / iPr-OH=3 / 1 (5 mL × 3). The mixed organic phase was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum to obtain PhBzL-61a (280 mg, 555 ml, yield 95.9%) as a brown oil.
[0203] Preparation of tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2S)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepine-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanete, PhBzL-61b To a mixture of PhBzL-61a (200 mg, 396 umol, 1.0 equivalent), tert-butyl 3-[2-[2-[2-[2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanate (348 mg, 594 umol, 1.5 equivalents), and DIEA (102 mg, 793 umol, 138 uL, 2 equivalents), HATU (151 mg, 396 umol, 1.0 equivalent) was added all at once under N2 conditions at 0°C, stirred at 0°C for 30 minutes, then heated to 25°C and stirred for a further 0.5 hours. The reaction mixture was filtered, and the filtrate was separated and purified by HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 5%~55%, 8 min) to obtain PhBzL-61b (250 mg, 233 umol, yield 58.8%) as a yellow oil.
[0204] Preparation of 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(2S)-1-[4-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]benzoyl]pyrrolidine-2-carbonyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-61c To a solution of PhBzL-61b (120 mg, 112 umol, 1.0 equivalent) in MeCN (1 mL) and H2O (2 mL), HCl (12 M, 280 uL, 30 equivalents) was added all at once at 25°C under N2 conditions, and then the mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated under vacuum to obtain PhBzL-61c (110 mg, 108 umol, yield 96.7%) as a yellow oil.
[0205] Preparation of PhBzL-61 To a mixture of PhBzL-61c (110 mg, 108 umol, 1.0 equivalent) and (2,3,5,6-tetrafluoro-4-hydroxyphenyl)sulfonyloxysodium (145 mg, 541 umol, 5.0 equivalents) in DCM (2 mL) and DMA (0.3 mL), EDCI (103 mg, 541 umol, 5.0 equivalents) was added all at once under N2 conditions at 25°C and stirred at 25°C for 1 hour. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC (column: Phenomenex Synergi C18 150 × 25 × 10 μm, mobile phase: [water (0.1% TFA)-ACN], B%: 20%~45%, 8 min) to obtain PhBzL-61 (26.3 mg, 20.1 umol, yield 18.5%, purity 94.9%) as a flax-colored solid. 1H NMR (400 MHz, MeOD) δ7.86-7.74 (m, 5H), 7.71-7.66 (m, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 4.63-4.42 (m, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.88 (t, J = 6.0 Hz, 2H), 3.78 (t, J = 7.2 Hz, 4H), 3.71-3.55 (m, 38H), 3.49-3.40 (m, 5H), 2.99 (t, J = 6.0 Hz, 2H), 2.43-2.31 (m, 1H), 2.11-1.99 (m, 2H), 1.97-1.87 (m, 1H), 1.80 (d, J = 7.2 Hz, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.2 Hz, 3H). LC / MS[M+H]1144.5 (calculated value), LC / MS[M+H]1144.3 (observed value).
[0206] Example L-62 Synthesis of 4-((3-(2-(2-(2-((3-(2-amino-4-(ethoxy(propyl)carbamoyl)-3H-benzo[b]azepine-8-yl)phenyl)sulfonamide)ethoxy)ethoxy)ethoxy)propanoyl)oxy)2,3,5,6-tetrafluorobenzenesulfonic acid, PhBzL-62 [ka] Preparation of tert-butyl 3-[2-[2-[2-[(3-bromophenyl)sulfonylamino]ethoxy]ethoxy]ethoxy]propanate, PhBzL-62c To a mixture of tert-butyl 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanoate and PhBzL-62b (0.47 g, 1.69 mmol, 1 equivalent) in DCM (5 mL), Et3N (514 mg, 5.08 mmol, 708 μL, 3 equivalents) and 3-bromobensulfonyl chloride, PhBzL-62a (433 mg, 1.69 mmol, 245 μL, 1 equivalent) were added at 0°C, and the mixture was then stirred at 20°C for 3 hours. The mixture was washed with water (5 mL), and the organic phase was dried over Na2SO4 and concentrated to obtain PhBzL-62c (0.8 g, 1.61 mmol, yield 95.1%) as a colorless oil. 1 H NMR (400MHz, MeOD) δ8.10 (d, J = 1.6 Hz, 1H), 7.96-7.83 (m, 2H), 7.59 (t, J = 7.8 Hz, 1H), 3.79 (t, J = 6.4 Hz, 2H), 3.72-3.64 (m, 6H), 3.60-3.52 (m, 4H), 3.18-3.14 (m, 2H), 2.57 (t, J = 6.4 Hz, 2H), 1.54 (s, 9H).
[0207] Preparation of tert-butyl 3-[2-[2-[2-[[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethoxy]propanate, PhBzL-62e To a mixture of PhBzL-62c (300 mg, 605 umol, 1 equivalent) and 2-amino-N-ethoxy-N-propyl-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-1-benzazepine-4-carboxamide, and PhBzL-62d (250 mg, 605 umol, 1 equivalent) in dioxane (10 mL) and H2O (1 mL), Pd(dppf)Cl2 (22.1 mg, 30.2 umol, 0.05 equivalent) and K2CO3 (209 mg, 1.51 mmol, 2.5 equivalent) were added, and the mixture was stirred at 100°C for 1 hour under N2. The mixture was filtered through Celite and concentrated to obtain a residue. The residue was diluted with  (20 mL) and water (10 mL). The organic layer was separated, dried over Na2SO4, and concentrated to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 30%~55%, 8 min) to obtain PhBzL-62e (0.2g, 285umol, yield 47.0%) as a colorless oil. LC / MS[M+H]703.3 (calculated value), LC / MS[M+H]703.2 (observed value).
[0208] Preparation of 3-[2-[2-[2-[[3-[2-amino-4-[ethoxy(propyl)carbamoyl]-3H-1-benzazepin-8-yl]phenyl]sulfonylamino]ethoxy]ethoxy]ethoxy]propanoic acid, PhBzL-62f A mixture of PhBzL-62e (240 mg, 341 umol, 1 equivalent) in water (10 mL) was mixed with HCl (12 M, 569 μL, 20 equivalents) and then stirred at 80°C for 0.5 hours. The mixture was concentrated to obtain PhBzL-62f (0.2 g, 309 umol, yield 90.6%) as a yellow oil. LC / MS[M+H] 647.3 (calculated value), LC / MS[M+H] 647.3 (observed value).
[0209] Preparation of PhBzL-62 To a mixture of PhBzL-62f (0.2 g, 309 ml, 1 equivalent) and sodium 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonate (415 mg, 1.55 mmol, 5 equivalents) in DMA (0.3 mL) and DCM (3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, EDCI, CAS Reg. No. 1892-57-5 (296 mg, 1.55 mmol, 5 equivalents) was added, and the mixture was stirred at 20°C for 0.5 hours. The mixture was concentrated to obtain the residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150×25×10um, mobile phase: [water (0.1% TFA)-ACN], B%: 15%~45%, 8 min) to obtain PhBzL-62 (80.7 mg, 87.4 umol, yield 28.3%, purity 94.70%) as a white solid. 1 H NMR (400MHz, MeOD) δ8.18 (d, J = 1.6 Hz, 1H), 8.02-7.83 (m, 2H), 7.81-7.63 (m, 4H), 7.46 (s, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.90-3.71 (m, 4H), 3.69-3.42 (m, 12H), 3.16-3.10 (m, 2H), 2.96 (t, J = 5.6Hz, 2H), 1.88-1.69 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.2Hz, 3H). LC / MS[M+H]875.2 (calculated value), LC / MS[M+H]875.3 (observed value).
[0210] Example 201 Preparation of immune complexes (ICs) To prepare lysine conjugate immunoconjugates, the antibody is buffer-exchanged using a G-25 SEPHADEX® desalting column (Sigma-Aldrich, St. Louis, MO) or a Zeba® spin desalting column (Thermo Fisher Scientific) to a conjugation buffer containing 100 mM boric acid, 50 mM sodium chloride, and 1 mM ethylenediaminetetraacetic acid at pH 8.3. The eluates are then adjusted to a concentration of approximately 1–10 mg / ml using the buffer, and then filtered to a sterile state. The antibody is preheated to 20–30°C and rapidly mixed with 2–20 (e.g., 7–10) molar equivalents of tetrafluorophenyl (TFP) or tetrafluorophenyl sulfonate (sulfoTFP) ester of formula II, or an 8-phenyl-2-aminobenzazepine-linker (PhBzL) compound dissolved in dimethyl sulfoxide (DMSO) or dimethylacetamide (DMA) to a concentration of 5–20 mM. The reaction mixture is allowed to proceed at 30°C for approximately 16 hours, and the immunocomplexes (ICs) are separated from the reaction mixture by running two consecutive G-25 desalting columns or a Zeba® spin desalting column equilibrated in pH 7.2 phosphate-buffered saline (PBS) to provide the immunocomplexes (ICs) shown in Tables 3a and 3b. The adjuvant-antibody ratio (DAR) is determined by liquid chromatography-mass spectrometry using a C4 reversed-phase column on an ACQUITY® ULC H class (Waters Corporation, Milford, MA) connected to a XEVO® G2-XS TOF mass spectrometer (Waters Corporation).
[0211] To prepare cysteine conjugate immunocomplexes, antibodies were buffer-exchanged using a Zeba® spin desalting column (Thermo Fisher Scientific) to a conjugation buffer containing PBS with 2 mM EDTA, pH 7.2. Interchain disulfides were reduced using a 2–4 molar excess of tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT) at 37°C for 30 minutes to 2 hours. Excess TCEP or DTT was removed using a Zeba® spin desalting column pre-equilibriumized with the conjugation buffer. The concentration of the buffer-exchanged antibodies was adjusted to approximately 5–20 mg / ml using the conjugation buffer and filtered by sterile filtration. Maleimide-PhBzL compounds were dissolved in either dimethyl sulfoxide (DMSO) or dimethylacetamide (DMA) to a concentration of 5–20 mM. For conjugation, the antibody is mixed with 10–20 molar equivalents of maleimide-PhBzL. In some cases, up to 20% (v / v) of additional DMA or DMSO was added to improve the solubility of maleimide-PhBzL in the conjugation buffer. The reaction was allowed to proceed at 20°C for approximately 30 minutes to 4 hours. The resulting complex was purified from unreacted maleimide-PhBzL using two consecutive Zeba® spin desalting columns. The columns were pre-equilibriumated with phosphate-buffered saline (PBS) at pH 7.2. The adjuvant-to-antibody ratio (DAR) was estimated by liquid chromatography-mass spectrometry using a C4 reversed-phase column on an ACQUITY® ULC H class (Waters Corporation, Milford, MA) connected to a XEVO® G2-XS TOF mass spectrometer (Waters Corporation).
[0212] For conjugation, the antibody may be dissolved in an aqueous buffer system known in the art that does not adversely affect the antibody's stability or antigen-binding specificity. Phosphate-buffered saline may be used. The PhBzL compound is dissolved in a solvent system comprising at least one polar aprotic solvent, as described elsewhere in this specification. In some such embodiments, PhBzL is dissolved in pH 8 Tris buffer (e.g., 50 mM Tris) at concentrations in the range of about 5 mM, about 10 mM, about 20 mM, about 30 mM, about 40 mM, or about 50 mM, and about 5 mM to about 50 mM, or about 10 mM to about 30 mM. In some embodiments, PhBzL is dissolved in DMSO (dimethyl sulfoxide), DMA (dimethylacetamide), acetonitrile, or another suitable bipolar aprotic solvent.
[0213] Alternatively, in the conjugation reaction, an equivalent excess of PhBzL solution may be diluted and combined with the antibody solution. The PhBzL solution can be appropriately diluted with at least one polar aprotic solvent and at least one polar protic solvent, examples of which include water, methanol, ethanol, n-propanol, and acetic acid. The molar equivalents of the 8-Het-2-aminobenzazepine-linker intermediate to the antibody may be in the range of about 1.5:1, about 3:1, about 5:1, about 10:1, about 15:1, or about 20:1, and about 1.5:1 to about 20:1, about 1.5:1 to about 15:1, about 1.5:1 to about 10:1, about 3:1 to about 15:1, about 3:1 to about 10:1, about 5:1 to about 15:1, or about 5:1 to about 10:1. The reaction can be suitably monitored to complete by methods known in the art, such as LC-MS. The conjugation reaction is typically complete within a range of approximately 1 to 16 hours. After the reaction is complete, the reaction may be quenched by adding reagents to the reaction mixture. If the antibody thiol group has reacted with a thiol-reactive group such as 8PhBzL maleimide, the unreacted antibody thiol group may be reacted with a capping reagent. A suitable example of a capping reagent is ethyl maleimide.
[0214] After conjugation, the immunocomplex can be purified by purification methods known in the art, such as size exclusion chromatography, hydrophobic interaction chromatography, ion exchange chromatography, chromatofocusing, ultrafiltration, centrifugal ultrafiltration, tangential flow filtration, and combinations thereof, and separated from the non-conjugated reactants and / or conjugated aggregates. For example, before purification, the immunocomplex may be diluted in 20 mM sodium succinate, pH 5, etc. The diluted solution is spread onto a cation exchange column and subsequently washed with, for example, at least 10 column volumes of 20 mM sodium succinate, pH 5. The complex may be suitably eluted with a buffer such as PBS.
[0215] Example 202 HEK Reporter Assay HEK293 reporter cells expressing human TLR7 or human TLR8 were purchased from Invivogen, and cell proliferation and experiments were performed according to the vendor protocol. Briefly, the cells were grown to 80-85% fusion in DMEM supplemented with 10% FBS, Zeocin, and Blasticidin at 5% CO2. Subsequently, 4 × 10⁶ cells were subjected to HEK detection medium and a substrate containing immunostimulatory molecules. 4 Cells were seeded into 96-well plates with a cell / well ratio. Activity was measured using a plate reader at wavelengths of 620–655 nm.
[0216] Example 203 Evaluation of immune complex activity in vivo This embodiment demonstrates that the immune complex of the present invention is effective in inducing immune activation and is therefore useful in the treatment of cancer.
[0217] a) Isolation of human antigen-presenting cells: Human bone marrow antigen-presenting cells (APCs) were negatively selected from human peripheral blood obtained from healthy donors (Stanford Blood Center, Palo Alto, California) by density gradient centrifugation using the ROSETTESEP® human monocyte enrichment cocktail (Stem Cell Technologies, Vancouver, Canada), which contains monoclonal antibodies against CD14, CD16, CD40, CD86, CD123, and HLA-DR. Subsequently, immature APCs were purified to a purity of over 90% by negative selection using the EASYSEP® human monocyte enrichment kit (Stem Cell Technologies), which does not deplete CD16 and contains monoclonal antibodies against CD14, CD16, CD40, CD86, CD123, and HLA-DR.
[0218] b. Myeloid APC activation assay: 2 × 10 5 APCs are incubated in a 96-well plate (Corning, Corning, NY) containing 10% FBS, 100 U / mL penicillin, 100 μg / mL (micrograms / milliliter) streptomycin, 2 mM L-glutamine, sodium pyruvate, iscove's modified dulbecco's medium supplemented with non-essential amino acids, IMDM (Lonza), and, where indicated, various concentrations of unconjugated (naked) antibodies and immune complexes of the invention (prepared according to the above examples). Cell-free supernatants are analyzed after 18 hours via ELISA to measure TNFα secretion as a readout of the pro-inflammatory response.
[0219] c) PBMC activation assay: Human peripheral blood mononuclear cells were isolated from human peripheral blood obtained from healthy donors (Stanford Blood Center, Palo Alto, California) by density gradient centrifugation. PBMCs were incubated in 96-well plates (Corning, NY) co-cultured with CEA-expressing tumor cells (e.g., MKN-45, HPAF-II) at an effector-to-target cell ratio of 10:1. Cells were stimulated with various concentrations of unconjugated (naked) antibodies and immune complexes (prepared according to the examples above) of the present invention. Cell-free supernatant was analyzed by cytokine bead array using the LegendPlex® kit, in accordance with the manufacturer's guidelines (BioLegend®, San Diego, CA).
[0220] d) Isolation of conventional human dendritic cells: Conventional human dendritic cells (cDCs) were negatively selected from human peripheral blood obtained from healthy donors (Stanford Blood Center, Palo Alto, California) by density gradient centrifugation. Briefly, first, cells were enriched using the RosetteSep® human CD3 depletion cocktail (Stem Cell Technologies, Vancouver, Canada) to remove T cells from the cell preparation. Then, cDCs were further enriched by negative selection using the EASYSEP® human myeloid DC enrichment kit (Stem Cell Technologies).
[0221] e) cDC activation assay: 8 × 10 4The APCs were co-cultured with tumor cells expressing the ISAC target antigen in an effector (cDC) to target (tumor cell) ratio of 10:1. The cells were incubated in 96-well plates (Corning, Corning, NY) containing RPMI-1640 medium supplemented with 10% FBS and, where indicated, various concentrations of the indicated immunocomplexes (prepared according to the above examples) according to the present invention. After approximately 18 hours of overnight incubation, the cell-free supernatant was collected and analyzed for cytokine secretion (including TNFα) using a BioLegend LEGENDPLEX cytokine bead array.
[0222] Myeloid cell type activation can be measured using various screen assays in addition to the described assays that utilize different myeloid populations. These may include monocytes isolated from healthy donor blood, M-CSF differentiated macrophages, GM-CSF differentiated macrophages, GM-CSF+IL-4 monocyte-derived dendritic cells, conventional dendritic cells (cDCs) isolated from healthy donor blood, and myeloid cells polarized to an immunosuppressive state (also referred to as myeloid suppressor cells or MDSCs). Examples of MDSC polarized cells include M2aMΦ(IL4 / IL13), M2cMΦ(IL10 / TGFb), GM-CSF / IL6 MDSCs, and monocytes differentiated toward an immunosuppressive state such as tumor-educated monocytes (TEMs). TEM differentiation can be performed using tumor-conditioning media (e.g., 786.O, MDA-MB-231, HCC1954). Primary tumor-associated myeloid cells may also include primary cells present in dissociated tumor cell suspensions (Discovery Life Sciences).
[0223] The activation of a described population of bone marrow cells can be evaluated as a single culture or as a co-culture with cells expressing the antigen of interest, to which immune complexes can bind via the CDR region of the antibody. After 18–48 hours of incubation, activation can be evaluated by upregulation of cell surface costimulatory molecules using flow cytometry or by measurement of secreted pro-inflammatory cytokines. For cytokine measurement, cell-free supernatant is collected and analyzed using a cytokine bead array (e.g., LegendPlex from Biolegend) with flow cytometry.
[0224] All references cited herein, including publications, patent applications, and patents, are incorporated herein by reference as if they were included herein, each reference being individually and specifically incorporated by reference.
Claims
1. 1. The method of claim 1, further comprising administering to said patient an antibody covalently linked by a linker to one or more 8-phenyl-2-aminobenzazepine moieties, said antibody comprising said compound of formula I: Ab-[L-PhBz] p I An immune complex having the formula: During the ceremony, Ab is an antibody construct having an antigen-binding domain that binds to HER2; p is an integer from 1 to 8; PhBz has the formula: 【Chemistry 1】 and R 1 , R 2 , R 3 , and R 4 However, independently, H, C 1 -C 12 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, C 3 -C 12 Carbocyclyl, C 6 -C 20 Aryl, C 2 -C 9 Heterocyclyl, and C 1 -C 20 heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally selected from the group consisting of: - (C 1 -C 12 alkyldiyl)-N(R 5 ) - *, - (C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , - (C 1 -C 12 Alkyldiyl)-OR 5 , - (C 3 -C 12 Carbocyclyl), - (C 3 -C 12 Carbocyclyl)-*, - (C 3 -C 12 carbocyclyl)-(C 1 -C 12 Alkyldiyl)-NR 5 - *, - (C 3 -C 12 carbocyclyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , - (C 3 -C 12 carbocyclyl)-NR 5 -C(=NR 5 ) N.R. 5 - *, - (C 6 -C 20 Aryl), - (C 6 -C 20 Aryldiyl)-*, - (C 6 -C 20 Aryldiyl)-N(R 5 ) - *, - (C 6 -C 20 Aryldiyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, - (C 6 -C 20 Aryldiyl)-(C 1 -C 12 Alkyldiyl)-(C 2 -C 20 Heterocyclyldiyl)-*, - (C 6 -C 20 Aryldiyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , - (C 6 -C 20 Aryldiyl)-(C 1 -C 12 Alkyldiyl)-NR 5 -C(=NR 5a ) N (R 5 ) - *, - (C 2 -C 20 Heterocyclyl), - (C 2 -C 20 Heterocyclyl)-*, - (C 2 -C 9 Heterocyclyl)-(C 1 -C 12 Alkyldiyl)-NR 5 - *, - (C 2 -C 9 Heterocyclyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , - (C 2 -C 9 Heterocyclyl)-C(=O)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, - (C 2 -C 9 Heterocyclyl)-NR 5 -C(=NR 5a ) N.R. 5 - *, - (C 2 -C 9 Heterocyclyl)-NR 5 - (C 6 -C 20 Aryldiyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, - (C 2 -C 9 Heterocyclyl)-(C 6 -C 20 Aryldiyl)-*, - (C 1 -C 20 Heteroaryl), - (C 1 -C 20 Heteroaryl)-*, - (C 1 -C 20 Heteroaryl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, - (C 1 -C 20 Heteroaryl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , - (C 1 -C 20 Heteroaryl)-NR 5 -C(=NR 5a ) N (R 5 ) - *, - (C 1 -C 20 Heteroaryl)-N(R 5 ) C(=O)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, -C(=O)-*, -C(=O)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, -C(=O)-(C 2 -C 20 Heterocyclyldiyl)-*, -C(=O)N(R 5 ) 2 、 -C(=O)N(R 5 )-*、 -C(=O)N(R 5 )-(C 1 -C 12 alkyldiyl)-N(R 5 ) C(=O)R 5 , -C(=O)N(R 5 )-(C 1 -C 12 alkyldiyl)-N(R 5 )C(=O)N(R 5 ) 2 , -C(=O)NR 5 - (C 1 -C 12 alkyldiyl)-N(R 5 ) CO 2 R 5 , -C(=O)NR 5 - (C 1 -C 12 alkyldiyl)-N(R 5 ) C(=NR 5a ) N (R 5 ) 2 , -C(=O)NR 5 - (C 1 -C 12 Alkyldiyl)-NR 5 C (=NR 5a ) R 5 , -C(=O)NR 5 - (C 1 -C 8 Alkyldiyl)-NR 5 (C 2 -C 5 Heteroaryl), -C(=O)NR 5 - (C 1 -C 20 Heteroaryldiyl)-N(R 5 ) - *, -C(=O)NR 5 - (C 1 -C 20 Heteroaryldiyl)-*, -C(=O)NR 5 - (C 1 -C 20 Heteroaryldiyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , -C(=O)NR 5 - (C 1 -C 20 Heteroaryldiyl)-(C 2 -C 20 Heterocyclyldiyl)-C(=O)NR 5 - (C 1 -C 12 Alkyldiyl)-NR 5 - *, -N(R 5 ) 2 、 -N(R 5 )-*、 -N(R 5 )C(=O)R 5 、 -N(R 5 )C(=O)-*、 -N(R 5 )C(=O)N(R 5 ) 2 、 -N(R 5 )C(=O)N(R 5 )-*、 -N(R 5 )CO 2 R 5 、 -NR 5 C(=NR) 5a )N(R 5 ) 2 、 -NR 5 C(=NR) 5a )N(R 5 )-*、 -NR 5 C(=NR) 5a )R 5 、 -N(R 5 ) C(=O)-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, -N(R 5 )-(C 2 -C 5 Heteroaryl), -N(R 5 ) -S(=O) 2 - (C 1 -C 12 alkyl), -O-(C 1 -C 12 alkyl), -O-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , -O-(C 1 -C 12 alkyldiyl)-N(R 5 ) - *, -O-C(=O)N(R 5 ) 2 、 -O-C(=O)N(R 5 )-*、 -S(=O) 2 - (C 2 -C 20 Heterocyclyldiyl)-*, -S(=O) 2 - (C 2 -C 20 Heterocyclyldiyl)-(C 1 -C 12 alkyldiyl)-N(R 5 ) 2 , -S(=O) 2 - (C 2 -C 20 Heterocyclyldiyl)-(C 1 -C 12 Alkyldiyl)-NR 5 -*, and -S(=O) 2 - (C 2 -C 20 Heterocyclyldiyl)-(C 1 -C 12 or substituted with one or more groups selected from: Or R 2 and R 3 together form a 5- or 6-membered heterocyclyl ring, X 1 , X 2 , X 3 , and X 4 are independently a bond, C(=O), C(=O)N(R 5 ), O, N(R 5 ), S, S(O) 2 , and S(O) 2 N (R 5 ) selected from the group consisting of R 5 However, independently, H, C 6 -C 20 Aryl, C 3 -C 12 Carbocyclyl, C 6 -C 20 Aryldiyl, C 1 -C 12 Alkyl, and C 1 -C 12 alkyldiyl, or two R 5 the groups taken together form a 5- or 6-membered heterocyclyl ring; R 5a But, C 6 -C 20 Aryl and C 1 -C 20 Heteroaryl; In the formula, the asterisk * indicates the binding site of L, and R 1 , R 2 , R 3 , and R 4 is attached to L; L, -C(=O)-PEG-, -C(=O)-PEG-C(=O)N(R 6 )-(C 1 -C 12 alkyldiyl)-C(=O)-Gluc-, -C(=O)-PEG-O-, -C(=O)-PEG-O-C(=O)-, -C(=O)-PEG-C(=O)-, -C(=O)-PEG-C(=O)-PEP-, -C(=O)-PEG-N(R 6 )-、 -C(=O)-PEG-N(R 6 )-C(=O)-、 -C(=O)-PEG-N(R 6 )-PEG-C(=O)-PEP-、 -C(=O)-PEG-N + (R 6 ) 2 2019-02-20 10:00:00 AM -C(=O)-PEG-C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)-, -C(=O)-PEG-C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)N(R 6 ) C(=O)-(C 2 -C 5 Monoheterocyclyldiyl)-, -C(=O)-PEG-SS-(C 1 -C 12 alkyldiyl)-OC(=O)-, -C(=O)-PEG-SS-(C 1 -C 12 alkyldiyl)-C(=O)-, -C(=O)-(C 1 -C 12 alkyldiyl)-C(=O)-PEP-, -C(=O)-(C 1 -C 12 alkyldiyl)-C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)-, -C(=O)-(C 1 -C 12 alkyldiyl)-C(=O)-PEP-N(R 6 )-(C 1 -C 12 alkyldiyl)-N(R 5 )-C(=O), -C(=O)-(C 1 -C 12 alkyldiyl)-C(=O)-PEP-N(R 6 )-(C 1 -C 12 alkyldiyl)-N(R 6 ) C(=O)-(C 2 -C 5 Monoheterocyclyldiyl)-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-C(=O)N(R 6 )-(C 1 -C 12 alkyldiyl)-C(=O)-Gluc-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-O-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-O-C(=O)-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-C(=O)-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-N(R 5 ) -, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-N(R 5 )-C(=O)-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-C(=O)-PEP-, -Succinimidyl-(CH 2 ) m -C(=O)N(R 6 )-PEG-SS-(C 1 -C 12 alkyldiyl)-OC(=O)-, -Succinimidyl-(CH 2 ) m -C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)-, -Succinimidyl-(CH 2 ) m -C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)N(R 6 ) C(═O)—, and -Succinimidyl-(CH 2 ) m -C(=O)-PEP-N(R 6 )-(C 1 -C 12 Alkyldiyl)N(R 6 ) C(=O)-(C 2 -C 5 the linker being selected from the group consisting of: R 6 are independently H or C 1 -C 6 is alkyl, PEG is a group represented by the formula: -(CH 2 CH 2 O) n - (CH 2 ) m -, m is an integer from 1 to 5, and n is an integer from 2 to 50; Gluc has the formula: 【Chemistry 2】 having PEP has the formula: 【Chemistry 3】 where AA are independently selected from natural or unnatural amino acid side chains, or one or more of AA and the adjacent nitrogen atom form a 5-membered ring proline amino acid, and the wavy line indicates the point of attachment; Cyc is optionally F, Cl, NO 2 , -OH, -OCH 3 and glucuronic acid having the structure: 6 -C 20 Aryldiyl and C 1 -C 20 heteroaryldiyl; 【Chemistry 4】 R 7 is -CH(R 8 ) O-, -CH 2 --, --CH 2 N (R 8 )- and -CH(R 8 )O—C(═O)—, wherein R 8 But, H, C 1 -C 6 Alkyl, C(=O)-C 1 -C 6 Alkyl, and -C(=O)N(R 9 ) 2 wherein R 9 However, independently, H, C 1 -C 12 Alkyl, and -(CH 2 CH 2 O) n - (CH 2 ) m -OH, wherein m is an integer from 1 to 5 and n is an integer from 2 to 50, or two R 9 the groups taken together form a 5- or 6-membered heterocyclyl ring; y is an integer from 2 to 12; z is 0 or 1; Alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally selected from F, Cl, Br, I, -CN, -CH 3 , -CH 2 CH 3 , -CH=CH 2 , -C≡CH, -C≡CCH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH (CH 3 ) 2 , -CH 2 OH, -CH 2 OCH 3 , -CH 2 CH 2 OH, -C(CH 3 ) 2 OH, -CH(OH)CH(CH 3 ) 2 , -C(CH 3 ) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3 , -CH 2 OP(O)(OH) 2 , -CH 2 F, -CHF 2 , -CF 3 , -CH 2 CF 3 , -CH 2 CHF 2 , -CH(CH 3 )CN, -C(CH 3 ) 2 CN, -CH 2 CN, -CH 2 N.H. 2 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N.H.C.H. 3 , -CH 2 N(CH 3 ) 2 、-CO 2 H、-COCH 3 、-CO 2 CH 3 、-CO 2 C(CH 3 ) 3 、-COCH(OH)CH 3 、-CONH 2 、-CONHCH 3 、-CON(CH 3 ) 2 、-C(CH 3 ) 2 P. 2 、-NH 2 、-NHCH 3 、-N(CH 3 ) 2 -NHCOCH 3 、-N(CH 3 )COCH 3 、-NHS(O) 2 CH 3 、-N(CH 3 )C(CH 3 ) 2 P. 2 、-N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 、-NHC(=NH)H, -NHC(=NH)CH 3 -NHC(=NH)NH 2 -NHC(=O)NH 2 、-NO 2 、=O、-OH、-OCH 3 、-OCH 2 CH 3 、-OCH 2 CH 2 SO 3 、-OCH 2 CH 2 H 2 CH 2 N(CH 3 ) 2 、-O(CH 2 CH 2 O) n -(CH 2 ) m CO 2 H, -O(CH 2 CH 2 O) n H, -OCH 2 F, -OCHF 2 , -OCF 3 , -OP(O)(OH) 2 , -S(O) 2 N (CH 3 ) 2 , -SCH 3 , -S(O) 2 CH 3 , and -S(O) 3 H, or a pharma- ceutically acceptable salt thereof.
2. The immunoconjugate of claim 1 , wherein the antibody is selected from trastuzumab and pertuzumab.
3. X 1 is a bond, and R 1 The immune complex according to any one of claims 1 and 2, wherein is H.
4. X 2 is a bond, and R 2 But, C 1 -C 8 The immunoconjugate of claim 1 or 2, which is alkyl.
5. X 2 and X 3 are each a bond, R 2 and R 3 But independently, C 1 -C 8 Alkyl, —O—(C 1 -C 12 alkyl), -(C 1 -C 12 Alkyldiyl)-OR 5 , -(C 1 -C 8 alkyldiyl)-N(R 5 ) CO 2 R 5 , -(C 1 -C 12 alkyl)-OC(O)N(R 5 ) 2 , -O-(C 1 -C 12 alkyl)-N(R 5 ) CO 2 R 5 , and —O—(C 1 -C 12 alkyl)-OC(O)N(R 5 ) 2 The immune complex according to claim 1 or 2, which is selected from the group consisting of
6. R 2 But, C 1 -C 8 alkyl, R 3 However, (C 1 -C 8 alkyldiyl)-N(R 5 ) CO 2 R 5 The immune complex of claim 5 ,
7. R 2 But -CH 2 CH 2 CH 3 and R 3 But -CH 2 CH 2 CH 2 N.H.C.O. 2 (t-Bu), -OCH 2 CH 2 N.H.C.O. 2 (cyclobutyl), and -CH 2 CH 2 CH 2 N.H.C.O. 2 7. The immunoconjugate of claim 6, wherein said aryl group is selected from the group consisting of aryl, ... and aryl.
8. R 2 and R 3 each independently represents -CH 2 CH 2 CH 3 , -OCH 2 CH 3 , -OCH 2 CF 3 , -CH 2 CH 2 CF 3 , -OCH 2 CH 2 OH and -CH 2 CH 2 CH 2 6. The immune complex of claim 5, wherein said amino acid is selected from the group consisting of OH.
9. R 2 and R 3 are each -CH 2 CH 2 CH 3 The immune complex of claim 8,
10. R 2 But -CH 2 CH 2 CH 3 and R 3 But, -OCH 2 CH 3 The immune complex of claim 8,
11. X 3 -R 3 but, 【Chemistry 5】 The immune complex according to any one of claims 1 and 2, selected from the group consisting of:
12. X 4 is a bond, and R 4 The immune complex according to any one of claims 1 and 2, wherein is H.
13. R 1 The immune complex according to claim 1 or 2, wherein:
14. R 2 Or R 3 The immune complex according to claim 1 or 2, wherein:
15. X 3 -R 3 -L is, 【Chemistry 6】 15. The immunoconjugate of claim 14, wherein the wavy line indicates the point of attachment to N.
16. The immunoconjugate according to any one of claims 1 and 2, wherein L is -C(=O)-PEG- or -C(=O)-PEG-C(=O)-.
17. 3. The immune complex of claim 1, wherein L is attached to a cysteine thiol of the antibody.
18. The immunoconjugate of any one of claims 1 and 2, wherein for the PEG, m is 1 or 2 and n is an integer from 2 to 10.
19. 19. The immune complex of claim 18, wherein n is 10.
20. L has the structure: 【Chemistry 12】 wherein the wavy line is selected from R 5 3. The immune complex of claim 1, which exhibits binding to
21. Formula Ia: 【Chemistry 13】 The immune complex according to claim 1 , having the formula:
22. X 4 is a bond, and R 4 The immune complex of claim 21 , wherein is H.
23. X 2 and X 3 are each a bond, R 2 and R 3 But independently, C 1 -C 8 Alkyl, —O—(C 1 -C 12 alkyl), -(C 1 -C 12 Alkyldiyl)-OR 5 , -(C 1 -C 8 alkyldiyl)-N(R 5 ) CO 2 R 5 , -(C 1 -C 12 alkyl)-OC(O)N(R 5 ) 2 , -O-(C 1 -C 12 alkyl)-N(R 5 ) CO 2 R 5 , and —O—(C 1 -C 12 alkyl)-OC(O)N(R 5 ) 2 The immune complex of claim 21 , selected from:
24. Formulae Ib to If: 【Chemistry 14-1】 【Chemistry 14-2】 The immune complex of claim 21 , selected from:
25. X 2 and X 3 are each a bond, R 2 and R 3 But independently, C 1 -C 8 Alkyl, —O—(C 1 -C 12 alkyl), -(C 1 -C 12 Alkyldiyl)-OR 5 , -(C 1 -C 8 alkyldiyl)-N(R 5 ) CO 2 R 5 , and —O—(C 1 -C 12 alkyl)-N(R 5 ) CO 2 R 5 25. The immune complex of claim 24, selected from:
26. X 2 and X 3 are each a bond, R 2 But, C 1 -C 8 alkyl, R 3 But -O-(C 1 -C 12 alkyl) and -O-(C 1 -C 12 alkyl)-N(R 5 ) CO 2 R 5 25. The immune complex of claim 24, selected from:
27. An 8-phenyl-2-aminobenzazepine-linker compound selected from the group consisting of:
28. 28. An immunoconjugate prepared by conjugation of an anti-HER2 antibody with the 8-phenyl-2-aminobenzazepine-linker compound of claim 27.
29. A pharmaceutical composition comprising a therapeutically effective amount of the immunoconjugate of any one of claims 1 and 2, and one or more pharma- ceutically acceptable diluents, vehicles, carriers, or excipients.
30. 30. Use of the immunoconjugate of any one of claims 1 to 28 for treating cancer, wherein the cancer is selected from cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, esophageal cancer, bladder cancer, urinary tract cancer, urothelial cancer, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.
31. A method for preparing an immunoconjugate of formula I according to claim 1, wherein the 8-phenyl-2-amino-thienoazepine-linker compound according to claim 27 is conjugated to said anti-HER2 antibody.
